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Molecular Properties of Serum Thymidine Kinase 1 and Use of 
the Canine Enzyme in Disease Monitoring 
Abstract 
Thymidine kinase 1 (ATP: thymidine 5'-phosphotransferase, EC 2.7.1.21, TK1) 
catalyzes the transfer of the gamma phosphate group from a phosphate donor to the 5´- 
hydroxyl group of thymidine to form thymidine monophosphate, which is converted to 
thymidine triphosphate and then utilized in DNA synthesis. TK1 activity markedly 
increases in G1 and S phase of the cell cycle and is found mainly in dividing cells, but 
also in an extracellular form in the blood. Increased serum TK1 levels are considered as 
a sensitive and useful marker for cell proliferation and detection of malignancy in 
clinical medicine. 
The  aim  of  this  study  was  to  investigate  the  molecular  characteristics  of  canine 
thymidine kinase 1 and utilize several anti-TK1 antibodies to a better understanding its 
role in disease prognostics, risk assessment, and monitoring of cancer development.  
Study I was undertaken to clarify the structure of recombinant, cellular and serum 
TK1  in  order  to  improve  the  usefulness  of  serum  TK1  (STK1)  as  a  proliferation 
biomarker in neoplastic diseases. Several forms of STK1 were observed with different 
enzymatic activities. The active form of STK1 was found mainly as an oligomer. Dimer 
and tetramer forms of STK1 were also seen in serum by immunoaffinity method, but 
they were enzymatically less active. Study II described a sensitive method using a [
3H]-
deoxythymidine phosphorylation assay to measure STK1 activity in dogs and humans 
with hematologic malignancies and dogs with solid tumors. The results revealed that 
the dThd phosphorylation assay was suitable for measurement of TK1 in hematologic 
malignancy (lymphoma and leukemia) and provided valuable information regarding the 
disease recurrence. Significant correlation was observed between the [
3H]-dThd assay 
and the TK1 activity assays, TK-REA and TK Liaison. However, STK1 activity levels 
in dogs with solid tumors were very low. Therefore, another method to determine the 
levels of TK1 in serum based on immunoaffinity techniques was performed in study 
III. The concentration of STK1 protein in dogs with solid tumors was much higher than 
expected  from  the  activity.  Thus,  methods  to  determine  STK1  protein  are  more 
sensitive than activity tests in solid tumors. Study IV revealed that serum TK1 activity 
was elevated in 41% of bitches with pyometra, and thus TK1 determinations may be 
clinically valuable also in some non-neoplastic diseases. 
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pyometra, radio- enzymatic assay, immunoaffinity technique, cell proliferation marker. 
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 Abbreviations 
ADP  Adenosine diphosphate 
AMP  Adenosine monophosphate 
APC  Anaphase promoting complex 
ATP  Adenosine triphosphate 
AZT  3’-azidothymidine 
AZTMP  3’-azidothymidine monophosphate 
Cdk1  Cyclin dependent kinase 1 
cDNA  Complementary DNA 
CO2  Carbon dioxide 
D4T  2'-3'-didehydro-2'-3'-dideoxythymidine 
dAdo  Deoxyadenosine 
dCDP  Deoxycytidine diphosphate 
dCK  Deoxycytidine kinase 
dCMP  Deoxycytidine monophosphate 
dCTP  Deoxycytidine triphosphate 
dCyd  Deoxycytidine 
dGK  Deoxyguanosine kinase 
dGuo  Deoxyguanosine 
dN  Deoxyribonucleoside 
dNDP  Deoxyribonucleoside diphosphates 
dNK  Deoxyribonucleoside kinases 
dNMDK  Deoxyribonucleoside diphosphate kinases 
dNMPK  Deoxyribonucleoside monophosphate kinases 
dNTP  Deoxyribonuceloside triphosphates 
dTDP  Deoxythymidine diphosphate 
dTTP  Deoxythymidine triphosphate 
dUDP  Deoxyuridine diphosphate 
dUMP  Deoxyuridine monophosphate 9 
dUTP  Deoxyuridine triphosphate 
FdUrd  5-fluoro-2′-deoxyuridine 
FLT  3′-deoxy-3′-fluorothymidine 
GMP  Guanosine monophosphate 
IMP  Inosine monophosphates 
mtDNA  Mitochondrial DNA 
NDP  Riboucleoside diphosphates 
NMP  Riboucleoside monophosphates 
NTP  Ribonucleoside triphosphates 
TK1  Thymidine kinase 1, cytosolic 
TK2  Thymidine kinase 2, mitochondrial 
TMP  Thymidine monophosphate 
TS  Thymidylate synthase 
UMP  Uridine monophosphate 
UTP  Uridine triphosphate 
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1  Introduction 
1.1  Blood biomarkers in veterinary medicine 
Disease diagnosis and efficacy of therapeutic interventions are major clinical 
challenges in veterinary medicine. The ideal biomarker for a certain disease 
should be sensitive and specific enough to distinguish  between  healthy and 
disease states. Thus, provide reliable information about the progression of the 
disease and the response to therapy as well as predict the recurrence of disease, 
particularly in tumor.  
1.1.1  Infectious disease biomarkers 
An infection is a disease caused by the invasion of body tissues by bacteria, 
viruses, parasites and fungi or results from the toxins that they produce. Hosts 
mainly  fight  against  these  agents  via  the  immune  system.  Therefore, 
inflammatory mediators are released into the blood at the site of infection.  
The  majority  of  new  blood  biomarkers  are  part  of  the  systemic 
inflammatory  response.  Many  inflammatory  actors  often  use  as  disease 
markers in the clinical setting, e.g. white blood cells, neutrophils, monocytes, 
lymphocytes, eosinophils and basophiles. Any changes in the number, size and 
morphology  of  these  cells  represent  inflammation,  infection  or  immune- 
mediated disease. Low numbers of some of these inflammatory cells indicate 
bone marrow suppression or septic shock.  
The acute phase proteins (APPs) are blood proteins released in response to 
infection,  inflammation  or  trauma  (Young  et  al.,  1991).  The  acute  phase 
proteins such as C-reactive protein, serum amyloid A, haptoglobin and α1 – 
acid  glycoprotein  are  widely  used  as  diagnostic,  prognostic  and  monitoring 
markers (Ceron et al., 2005; Murata et al., 2004; Petersen et al., 2004). The 
acute phase proteins are induced by cytokines such as interleukins IL - 1, IL - 6 
and tumor necrosis factor alpha (TNF-α), and they stimulate the hepatocytes to 
produce APPs (Young et al., 1991). The cytokines are themselves considered 12 
as diagnostic markers for systemic inflammation (Song et al., 2012; Rau et al., 
2007).  
Some biochemical markers are elevated in certain diseases, i.e. elevation of 
alkaline  phosphatase  and  aspartate  transferase,  which  indicating  diseases 
involving the liver. Elevation of creatinine and blood urea nitrogen indicates 
kidney disease. 
1.1.2  Cell proliferation biomarkers 
A  tumor  is  an  abnormal  mass  of  tissue  that  has  no  function  in  the  body. 
Tumors are usually classified as benign or malignant. A benign tumor is not 
cancer. It is slow growing, does not spread or invade surrounding tissue, and 
once it is completely removed, it usually does not recur. A malignant tumor, on 
the other hand, is cancer that has the capacity to produce metastatic disease. 
However, certain "benign" tumors may later give rise to malignant cancers, 
which result from additional genetic changes in a subpopulation of the tumor's 
neoplastic cells. Thus, early diagnosis of cancer offers the best opportunity for 
treatments and increased survival rate.  
Tumor  markers  are any  substances  that  can  be  found  in  the  body  when 
malignant cells are present. Good tumor markers can significantly reduce the 
diagnostic  lead  time  and  be  sensitive  enough  in  screening  of  the  healthy 
population and populations at risk for the presence of malignancy. This will 
lead to  early  detection  of tumors and thus rescue  or at least prolonged life 
expectancy.  These  markers  may also  help  to  determine the effectiveness  of 
therapy and predict recurrence of the disease. 
Only limited numbers of tumor markers have been used for  monitoring 
proliferation,  i.e.  Ki-67,  Proliferating  Cell  Nuclear  Antigen  (PCNA),  and 
argyrophilic  nuclear  organizing  region  (AgNOR);  these  are  measured  by 
immunohistochemistry. Other tumor markers that can be measured in serum or 
plasma, i.e. lactate dehydrogenase (LDH), α-fetoprotein (AFP) and acute phase 
proteins such as α-1- acid glycoprotein (α1AG) and C-reactive protein (CRP). 
There is a large group of tumor specific markers, e.g. PSA, CA 15-3, CA125 
and CYFRA-21-1. They have been used in the clinical setting, but  most  of 
them are neither sensitive nor specific enough for screening or diagnosis of 
cancer without the support of other clinical findings. The levels of these tumor 
markers often do not increase until the symptoms appear, or they are elevated 
in diseases other than tumor diseases (Perkins et al., 2003; Bates, 1991). 
Ki-67  is  a  nuclear  antigen  found  in  proliferating  cells,  which  can  be 
detected by monoclonal antibodies (Gerdes et al., 1983). For many years, Ki-
67 has been used to measure the number of proliferating cancer cells in any 
particular tumor by immunohistochemistry. Ki-67 is not present in the blood 13 
and is expressed at all stages of the cell cycle except G0; however, the peak is 
found in G2 and M phase (Gerdes et al., 1983). Ki-67 has been used as a cell 
proliferation marker in human with non Hodgkin’s lymphoma (Grogan et al., 
1988; Gerdes et al., 1987) and other solid tumors (Sahin et al., 1991). Some 
studies have been carried out to determine the diagnostic and prognostic value 
of  Ki-67  in  veterinary  medicine  (Ishikawa  et  al.,  2006;  Sakai  et  al.,  2002; 
Roels et al., 1999; Lohr et al., 1997). 
PCNA is a DNA clamp holder protein for DNA polymerase delta that plays 
an  important  role  in  DNA  replication  and  repair  (Naryzhny,  2008).  It  is 
involved in leading strand synthesis and appears in late G1 and S phase cells 
(Ishikawa et al., 2006; Bravo & Macdonald-Bravo, 1985).  
Drawbacks of PCNA and Ki-67 are the presence of Ki-67 throughout all 
phases of the cell cycle and the long half life of PCNA (20 h) can create false 
positive results (Bravo & Macdonald-Bravo, 1985). Furthermore, they cannot 
be measured in the blood.  
AgNORs are proteins associated with a loop of DNA in the nuclei where 
ribosomal RNA transcription occurs. The amount of AgNORs represents the 
percentage of cycling cells. It is widely used as a cell proliferation marker and 
provides information in  grading canine  malignant lymphoma (Kiupel et al., 
1998a; Vail et al., 1996; Preziosi et al., 1995). 
A  major  concern  with  this  marker  is  the  influence  of  several  technical 
parameters,  e.g.  fixation,  temperature  and  staining  of  tissue  on  the  results 
(Kiupel et al., 1998b).  
Serum levels of LDH are used as a prognostic and diagnostic marker in 
humans with hematologic malignancy (Kornberg & Polliack, 1980; Schneider 
et al., 1980; Ferraris et al., 1979). 
In  veterinary  medicine,  some  investigations  have  been  carried  out  to 
determine the value of LDH as a screening maker for different malignancies. 
However,  up-regulation  of  LDH  in  diseases  other  than  malignancies  and 
fluctuating levels among patients have demonstrated that LDH is of limited 
value  as  a  marker  in  canine  tumor  monitoring  (Marconato  et  al.,  2010; 
Marconato et al., 2009; Von Euler et al., 2006; Zanatta et al., 2003; Nakamura 
et al., 1997). 
Other tumor markers, e.g. α-fetoprotein, which is a fetal antigen, and α1AG 
and  CRP,  are  elevated  in  some  cases  such  as  hepatocellular  tumor  and 
lymphoma (Merlo et al., 2007; Lechowski et al., 2002; Ogilvie et al., 1993). 
However, these markers are also elevated in other than tumor diseases, e.g. 
inflammation, infection, and trauma (Young et al., 1991). 
Over the past several years, many studies in human medicine have been 
performed  and  lead  to  improve  diagnosis  at  an  early  stage  of  tumor;  one 14 
example is a prostate specific antigen (PSA). It is a protein produced by the 
prostate glands at low levels in healthy and high levels in men with malignant 
prostatic  disease  and  shows  a  correlation  with  tumor  stage  and  prostate 
volume. However, it is often also increased in benign prostatic hypertrophy, 
which limits its value as a screening test (Bates, 1991). 
 CA 15-3 is widely used as a tumor marker for breast cancer (Duffy, 2006). 
However, this tumor marker has low sensitivity and relatively low specificity 
in diagnostics of early stage disease. Its concentration is elevated about 10% in 
stage I and about 75% in stage IV (Brooks, 2009; Duffy, 2006). Besides breast 
cancer, CA 15-3 is also up-regulated in other diseases such as liver diseases, 
pulmonary cancer, gastrointestinal/colonic cancer and ovarian cancer (Brooks, 
2009). 
CA 125 is a glycoprotein produced by ovarian cancer cells and found in 
80%  of  women  with  ovarian  cancer  (Bates,  1991).  It  provides  valuable 
information regarding prognosis and recurrence of the disease (Diaz-Padilla et 
al., 2012). However, it has low sensitivity at the  early stage  of the  disease 
where  only  50%  of  patients  expressed  CA  125  (Sasaroli  et  al.,  2009). 
Furthermore, CA 125 is also lacking specificity, since  it is also elevated in 
other tumors, such as endometrial, breast and lung cancer (Bast et al., 1998). 
CYFRA-21-1 is a cytokeratin 19 fragment, produced by all types of lung 
cancers.  It  is  considered  as  the  most  sensitive  non-small  cell  lung  cancer 
(NSCLC)  marker.  CYFRA-21  levels  correlate  with  tumor  burden,  and  it 
appears to be a reliable biomarker for monitoring disease relapse and assesses 
the response to chemotherapy (Tufman & Huber, 2010). It is, however, highly 
expressed in some other diseases such as renal failure (Stieber et al.). 
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2  DNA precursor synthesis 
Deoxyribonucleoside triphosphates (dNTPs) are essential for all living cells. 
They are needed for the synthesis, maintenance and repair of DNA. The DNA 
precursors can be synthesized either by the de novo pathway or the salvage 
pathway, where dNs are reused from degraded DNA and the diet. An overview 
of the nucleotides metabolism in mammalian cells is shown in figure 1. 
2.1  The de novo pathway  
In de novo pathway ribonucleoside monophosphates are formed form ribos-5-
phosphate and other molecules such as amino acids and CO2, in the presence of 
energy  in the form  of ATP. IMP is the  first  purine  nucleotide synthesized. 
Subsequently,  it  is  converted  either  to  GMP  or  AMP.  The  ribonucleoside 
monophosphates  (NMPs)  will  be  further  phosphorylated  to  ribonucleoside 
diphosphates  (NDPs);  which  are  then  phosphorylated  to  ribonucleoside 
triphosphates  (NTPs)  for  RNA  synthesis,  or  reduced  by  ribonucleotide 
reductase to form the deoxyribonucleosides diphosphates (dNDPs) (Nordlund 
& Reichard, 2006; Reichard, 1988; Thelander & Reichard, 1979). The final 
phosphorylation  results  in  the  formation  of  dNTPs.  Deoxythymidine 
monophosphate  is  formed  through  methylation  of  deoxyuridine 
monophosphate by thymidylate synthase (TS). After further phosphorylation 
steps  deoxythymidine  triphosphate  (dTTP)  is  formed,  which  is  required  for 
DNA synthesis (Montfort & Weichsel, 1997). 
2.2   The salvage pathway 
This is a recycling pathway, where DNA precursors are produced by reusing 
deoxyribonucleosides (dNs), which come from DNA degradation either inside 
or outside the cell or from the diet. Specific transporter proteins transport dNs 
into the cell (Kong et al., 2004; Cass et al., 1999; Plagemann et al., 1988). 16 
Then dNs are phosphorylated by deoxyribonucleoside kinases to dNMPs. This 
step is usually the rate limiting step in the salvage pathway (Arner & Eriksson, 
1995)  and  leads  to  trapping  of  the  nucleotides  inside  cells.  Subsequent 
phosphorylation of the resulting nucleotides by NMPKs and NDPKs leads to 
the formation of dNDPs and dNTPs, respectively (Arner & Eriksson, 1995). 
 
 
 
 Figure 1. A schematic illustration of the synthesis of the DNA precursors, dCTP and dTTP. 
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2.3  Deoxyribonucleoside kinases (dNKs) 
dNKs are enzymes catalyzing the first step of phosphorylation in the salvage 
pathway by transferring a phosphoryl group from nucleoside triphosphates to 
deoxyribonucleosides.  
Mammalian  cells  have  four  different  dNKs  with  overlapping  substrate 
specificities. Two cytosolic dNKs, Thymidine kinase 1 (TK1, E.C. 2.7.1.21) 
and deoxycytidine kinase (dCK, E.C. 2.7.1.74) and two mitochondrial dNKs, 
thymidine kinase 2 (TK2, E.C. 2.7.1.21) and deoxyguanosine  kinase (dGK, 
E.C  2.7.1.113)  (Eriksson  et  al.,  2002).  The  comparison  of  the  amino  acid 
sequences of dCK, dGK, TK2 and TK1 reveals that all dNKs, except TK1, 
share some conserved motifs. Thus, the dNKs can be divided into two families; 
the TK1 group and the dCK, dGK, TK2 group (Eriksson et al., 2002). 
dNKs  are  of  medical  interests  as  they  are  involved  in  several  human 
diseases. For example, TK2 deficiency is associated  with  mtDNA depletion 
syndrome and leads to severe myopathy (Eriksson et al., 2002). Lack of dGK 
is also associated with mtDNA depletion and patients with no dGK activity die 
in infancy with liver failure and neurological abnormalities (Eriksson et al., 
2002). No human cases  with  TK1 deficiency  have been reported;  however, 
TK1  knockout  mice  have  shorten  life  span  and  die  with  kidney  failure 
(Dobrovolsky et al., 2003). 
dNKs  have  important  roles  in  antiviral  and  anticancer  therapy  through 
activation  of  nucleoside  analog  drugs.  The  first  step  in  this  activation  is 
phosphorylation  of  nucleoside  analogs  by  dNKs  to  nucleoside  analog 
monophosphates (NAMP). Subsequently, the NAMP is phosphorylated to di- 
and triphosphate by other cellular kinases (Van Rompay et al., 2000). Then the 
final product can be incorporated into viral or cellular DNA, which interferes 
with viral DNA synthesis or cellular DNA synthesis and repair, resulting in cell 
death (Leoni et al., 1998). 
dNKs are also important in suicide gene chemotherapy. In this therapy, a 
kinase gene is delivered and expressed in target cells, followed by treatment 
with nucleoside analog that are phosphorylated by the introduced kinase. This 
may results in termination of DNA replication and induces apoptosis in the 
cells that harbor the specific kinase gene. Many experimental studies have been 
done to model human cancers using TK from Herpes simplex virus type 1 for 
the selective activation of nucleoside analogs such as ganciclovir (Sterman et 
al., 2005; Rainov & Grp, 2000; Ural et al., 2000; Klatzmann et al., 1998). 18 
Deoxycytidine kinase (dCK) 
Deoxycytidine  kinase  (NTP:  deoxycytidine  5´-phosphotransferase,  E.C. 
2.7.1.74) is a cytoplasmic enzyme expressed preferentially in lymphocytic cells 
(Eriksson et al., 2002; Hatzis et al., 1998; Johansson et al., 1997). 
The dCK gene extends over more than 34 kb on chromosome 4q13.3-q21 
with 7 exons that vary in size from 90 to 1544 bp (Song et al., 1993; Chottiner 
et al., 1991). The enzyme has two identical subunits with a molecular weight 
of 30 kDa. The active form of the enzyme is a homodimer (60 kDa) (Bohman 
& Eriksson, 1988).  
dCK  has  a  broad  substrate  specificity  and  can  phosphorylate  both 
pyrimidine and purine deoxyribonucleosides and their analogs. These are of 
importance  in  antiviral  and  cancer  therapy  such  as  β-L-2´-3´-  dideoxy-3´- 
thiacytidine  (lamivudine),  arabinosyl  cytosine  (cytosar),  2-  chlorordeoxy- 
adenosine  (cladribine,  CdA)  and  diflourodeoxycytidine  (gemcitabine),  2- 
fluoro-arabinofuranosyl  adenine  (fludarabine,  FAraA),  2´-3´-dideoxycytidine 
(zalcitabine, ddc) and arabinosyl adenine (vidarabine, AraA) (Eriksson et al., 
2002; Eriksson et al., 1991a; Eriksson et al., 1991b). The enzyme does not 
follow  Michaelis–Menten  kinetics,  but  shows  negative  cooperativity  with  a 
Hill  constant  (n)  <1.  The  catalytic  efficiency  of  the  enzyme  for  natural 
substrates  and  their  analogs  are  extensively  studied  (Eriksson  et  al.,  2002). 
ATP  and  UTP,  as  well  as  other  nucleoside  triphosphates  can  serve  as 
phosphate donors (Krawiec et al., 2003; Krawiec et al., 1995). 
Deoxyguanosine kinase (dGK) 
Deoxyguanosine kinase (nucleoside triphosphate: deoxyguanosine 5´-phospho 
transferase, EC 2.7.1.113) is a mitochondrial enzyme and can be found in all 
tissues (Wang et al., 1993). However, dGK is found in the cytosol together 
with cytochrome c during apoptosis (Jullig & Eriksson, 2001). 
The gene is located on chromosome 2q13 and encodes a 30 kDa protein. 
dCK and dGK show similarity in the amino acids sequence, except in the N 
terminal  region,  which  could  be  due  to  that  they  have  different  subcellular 
localization. The active enzyme is a homodimer with a molecular weight of 60 
kDa (Wang et al., 1996; Wang et al., 1993). The catalytic efficiency of the 
enzyme for dGuo, dAdo and dCyd are 6 x10
-4 M
-1s
-1, 4 x10
-3 M
-1s
-1, and 1x10
-3 
M
-1s
-1, respectively (Eriksson et al., 2002). dGK can phosphorylate purines and 
a number of purines and pyrimidine nucleoside analogs but with the highest 
efficiency  for  the  purines  (Sjoberg  et  al.,  1998).  Several  nucleoside 
triphosphates can serve as phosphate donors, and preferentially ATP and UTP 
(Eriksson et al., 2002).  19 
Thymidine kinase 2 (TK2) 
Thymidine kinase 2 (ATP: thymidine 5´-phosphotransferase, E.C. 2.7.1.21) is 
localized in the mitochondria. TK2 is present in most tissue, and it is expressed 
independent of the cell cycle (Wang et al., 1993). TK2 has a broad substrate 
specificity,  which  differs  from  TK1,  since  it  can  phosphorylate 
deoxythymidine (dThd), deoxycytidine (dCyd) and deoxyuridine (dUrd) and 
their  analogs  (Munch-Petersen  et  al.,  1991).  The  level  of  TK2  is  low  in 
dividing  cells  as  compared  to  TK1;  however,  it  is  the  only  dThd 
phosphorylating  enzyme  found  in  non-dividing  cells.  TK2  can  be  found  in 
relatively  high  levels  in  liver,  spleen,  brain  and  pancreas  (Eriksson  et  al., 
2002).  
The TK2 gene is located on chromosome 16q22. The TK2 gene spans 45 kb 
with 10 exons that vary in size from 32 bp up to 1304 bp. The subunit size of 
mitochondrial TK2 is 28 kDa (Eriksson et al., 2002). The molecular profile of 
TK2 varies from monomer to hexamer; the first report revealed a dimer with 
MW of 70 kDa (Lee & Cheng, 1976). In a later report, TK2 had a molecular 
weight of f 98 kDa – 340 kDa as judged by G-200 Sephadex chromatography 
(Ellims & Van der Weyden, 1980). The monomer with a molecular weight of 
about 30 kDa and the active dimer has been described more recently (Wang et 
al., 2003; Munch-Petersen et al., 1991). 
The  kinetic  behavior  of  TK2  with  deoxythymidine  does  not  follow 
Michaelis-Menten  kinetics,  but  shows  negative  cooperatvity  with  a  Hill 
constant of n <1 (Wang et al., 2003). However, with other substrates dCyd and 
dUrd  the  activity  profile  follows  Michaelis-Menten  kinetics  (Wang  et  al., 
2003; Munch-Petersen et al., 1991). The Km values for dCyd and dUrd are 36 
 M and 6  M, respectively (Munch-Petersen et al., 1991). ATP and CTP serve 
as phosphate donors and the final products dTTP and dCTP act as feedback 
inhibitors (Munch-Petersen et al., 1991). 
Thymidine kinase 1 (TK1) 
Thymidine kinase 1 (ATP: thymidine 5´-phosphotransferase, EC 2.1.7.21) also 
catalyses  the  transfer  of  γ  phosphate  group  from  ATP  to  Thd  (and  dUrd) 
forming thymidine or deoxyuridine monophosphates. 
The TK1 gene is located on the long arm of chromosome 17 at position 
17q25.2-q25.3 (Petty et al., 1996; Elsevier et al., 1974; Miller et al., 1971). 
The first human TK1 cDNA was cloned and characterized almost 30 years ago 
(Flemington et al., 1987; Bradshaw & Deininger, 1984). The entire gene spans 
12.9 Kb with 7 exons. The cDNA is 1241 pb, with an open reading frame of 
702 pb coding for a protein of 234 amino acids with a molecular weight of 25 
kDa (Eriksson et al., 2002). 20 
The recent revolution in gene sequencing has revealed that mammalian and 
bird TK1;s from canine, mouse, rat, cattle and chicken (Zimin et al., 2009; 
Boardman et al., 2002; Strausberg et al., 2002) share high sequence identity to 
human  TK1,  with  89.3,  86.2,  87.0,  86.7  and  73.2%  sequence  identity, 
respectively. Most changes are seen in C-terminal regions (Fig. 2)  
Because of the importance of TK1 in different aspects of tumor diagnosis, it 
has  been  studied  for  many  years,  and  studies  on  the  cell  cycle  regulation, 
localization  in  the  cell,  enzyme  structure,  reaction  kinetics,  substrates 
specificity and medical interest will be described in the following sections. 
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Figure 1. Alignments of TK1 sequences from human, rat, mouse, dog, cow (Zimin et al., 2009; 
Boardman et al., 2002; Strausberg et al., 2002). Secondary structures of human are marked above 
the  alignment.  Red  boxes  indicate  the  cysteines  difference  among  the  species.  (*)  identical 
residues, (.) semi conserved residues, and (:) conserved residues. Gray boxes indicate KEN box 
motif. The alignment was done by ClustalW 2.1 program.  
 
 
 
   
Mouse      MSYINLPTVL PSSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC 50 
Rat        MSYINLPTVL PISPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC 50 
Human      MSCINLPTVL PGSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC 50 
Canine     MSCINLPTVL PGSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC 50 
Cattle     MSCINLPNVL PGSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQVAQYKC 50 
Chicken    MNCLTVPGVH PGSPGRPRGQ IQVIFGPMFS GKSTELMRRV RRFQLAQYRC 50 
           *. :.:* *  * **.:.*** ****:***** ********** ****:***:* 
 
Mouse      LVIKYAKDTR YSNS-FSTHD RNTMDALPAC MLRDVTQESL GVAVIGIDEG 100 
Rat        LVIKYAKDTR YSNS-FSTHD RNTMDALPAC MLKDVAQEAL GVAVIGIDEG 100 
Human      LVIKYAKDTR YSSS-FCTHD RNTMEALPAC LLRDVAQEAL GVAVIGIDEG 100 
Canine     LVIKYAKDTR YSNS-FSTHD RNTMEALPAC LLRDVAQEAL GVAVIGIDEG 100 
Cattle     LVIKYAKDTR YSSL-FSTHD RNTMEALPAC LLRDVIQDAQ RVAVIGIDEG 100 
Chicken    LLVKYAKDTR YCTTGVSTHD RNTMEARPAC ALQDVYQEAL GSAVIGIDEG 100 
           *::******* *..  ..*** ****:* ***  *:** *::    ******** 
 
Mouse      QFFPDIVDFC EMMANEGKTV IVAALDGTFQ RKAFGSILNL VPLAESVVKL 150 
Rat        QFFPDIVDFC ETMANTGKTV IVAALDGTFQ RKAFGSILNL VPLAESVVKL 150 
Human      QFFPDIVEFC EAMANAGKTV IVAALDGTFQ RKPFGAILNL VPLAESVVKL 150 
Canine     QFFPDIVEFS ETMANAGKTV IVAALDGTFQ RKAFGTILNL VPLAESVVKL 150 
Cattle     QFFPDIVEFC ENMANSGKTV IVAALDGTFQ RKAFGTILNL VPLAESVVKL 150  
Chicken    QFFPDIVEFC EKMANTGKTV IVAALDGTFQ RKAFGSILNL VPLAESVVKL 150 
           *******:*. * *** **** ********** **.**:**** ********** 
 
Mouse      TAVCMECFRE AAYTKRLGLE KEVEVIGGAD KYHSVCRLCY FKKSSAQTAG 200 
Rat        TAVCMECFRE ASYTKRLGLE KEVEVIGGAD KYHSVCRLCY FKKSSAQTAD 200 
Human      TAVCMECFRE AAYTKRLGTE KEVEVIGGAD KYHSVCRLCY FKKASGQPAG 200 
Canine     TAVCMECFRE AAYTKRLGSE KEVEVIGGAD KYHSVCRLCY FKKASGPPMG 200 
Cattle     TAVCMECFRE AAYTKRLGVE KEVEVIGGAD KYHSVCRLCY FKKASGQPAV 200 
Chicken    NAVCMECYRE ASYTKRLGAE REVEVIGGAD KYHSVCRACY FQKRPQQLGS 200 
           .******:** *:****** * :********* ******* ** *:* .  
 
Mouse      SDNKNCLVLG ---------Q PGEALVVRKL FASQQVLQYN SAN 233 
Rat        -NKENYSVLG ---------Q PIEIPAVRKL FAPQQILQCN SAN 232 
Human      PDNKENCP-- ------VPGK PGEAVAARKL FAPQQILQCS PAN 234 
Canine     LDSRENKENV LVLVPGKPGE GKEATGVRKL FAPQHVLQCS PAN 242 
Cattle     LDSEENKEN- ---CPMTLGK PAEAPGVRKL FATHQIWQCS QAN 238 
Chicken    ENKENVPMG- --------VK QLDMPASRKI FAS------- --- 224 
            :..:              :   :    **:* *.  
β1 β2
β2 β3 β4
β5 β6
βribbon βribbon
α1
α2
α3 α4
α522 
 
 
 
 
 
 23 
3  Thymidine kinase 1 
Thymidine kinase 1 differs from other deoxyribonucleoside kinases regarding 
the amino acid sequence, cell cycle regulation, structure, substrate specificity 
and kinetics. This section will focus on some of these properties.  
3.1  Molecular weights and enzyme kinetics 
Results on the kinetics behavior and molecular weights of human TK1 vary 
greatly between different investigations, most likely due to a different source 
and purity of the enzyme. TK1 purified from acute myelocytic leukemia, and 
placenta reveals native molecular weights of 90 and 92 kDa, respectively, with 
apparent Km values for dThd of 2.6 and 3  M, respectively (Gan et al., 1983; 
Lee & Cheng, 1976). In the absence of ATP the molecular weight of TK1, 
partially  purified  from  lymphocytes,  ranged  from  70-75  kDa,  while  in  the 
presence of 2 mM ATP the molecular weight increased 2-3 fold (170-200 kDa) 
(Munch-Petersen, 1984). It was shown that TK1 phosphorylated FdUrd better 
than dUrd with Km values of 2.2 and 9  M, respectively. AZT and FLT were 
also phosphorylated by TK1 but not D4T; the Km values were 0.6 and 2.2  M, 
respectively (Munch-Petersen et al., 1991).  
In  1993,  further  studies  on  the  effect  of  ATP  were  carried  out,  and  a 
transition from a dimer with 50 kDa to a tetramer with 100 kDa was observed 
(Munch-Petersen et al., 1993). This tetramerization was also accompanied by a 
change in the kinetic behavior of the enzyme. The dimer showed hyperbolic 
kinetics with negative cooperativity and a K0.5 value of 12-16  M. However, 
the tetramer form had hyperbolic Michaelis-Menten kinetics with low Km value 
(0.4-0.7  M). Both dimer and tetramer forms had the same maximum velocity 
and hence, the catalytic efficiency of the tetramer was about 30-fold higher 
than the dimer (Munch-Petersen, 2009; Munch-Petersen et al., 1995a; Jensen 
& Munch-Petersen, 1994; Munch-Petersen et al., 1993).  24 
The dimer-tetramer transition was not only dependent on the presence of ATP 
but also on the enzyme concentration (Munch-Petersen et al., 1995a), since, 
oligomerization was seen with a high concentration of enzyme (0.2-20 mg/ml) 
in the absence of ATP (Munch-Petersen, 2009; Birringer et al., 2006). 
The  Km  values  for  ATP  were  30-50   M and  positive  cooperativity  was 
observed with Hill coefficients of 2.0-2.4 (Munch-Petersen, 1984). The Km for 
the dimer form was 100-170  M, and tetramer 10-20  M (Munch-Petersen et 
al., 1995a).  
The end product dTTP is a feedback inhibitor for TK1. The IC50 values 
were 9-21  M dTTP at varying concentrations of dThd. The IC50 values were 
3-36   M  dTTP  when  different  concentrations  of  ATP  were  used  (Munch-
Petersen, 1984). The inhibition kinetics of dTTP were similar for the tetramer 
and dimer forms with Hill coefficients of 2.5 for the tetramer and 2.7 for the 
dimers of TK1 (Munch-Petersen et al., 1995b). 
3.2  Cell cycle regulation 
Unlike other deoxynuceloside kinases, TK1 activity fluctuates greatly during 
the cell cycle. The enzyme reaches its maximum level during S phase (about 
15-fold compared to the minimum level in G1) in actively cycling cells. This 
increase does not correlate with TK mRNA levels, which increase only 3-fold 
as compared with G1 phase (Sherley & Kelly, 1988).  
In serum stimulated quiescent cells and simian virus 40-infected cells, TK1 
activity increased in parallel with increased TK1 mRNA levels (Coppock & 
Pardee, 1987; Stewart et al., 1987). These findings suggest that the regulatory 
mechanisms for TK1 expression are controlled at the transcriptional and post-
transcriptional level during the cell cycle. 
The half life of the TK1 polypeptide during M phase is reduced from 40 h 
to less than 1 h, resulting in removal of the TK1 protein from newly divided 
cells (Sherley & Kelly, 1988). This finding indicates a specific  degradation 
mechanism for TK1. Deletion of 40 amino acids at C-terminal region of human 
TK1  led  to  stabilization  of  the  enzyme  throughout  all  cell  cycle  phases. 
However, no alteration in cell cycle regulation was observed when only 10 C- 
terminal residues were removed (Zhu et al., 2006; Kauffman & Kelly, 1991).  
In 2004, a KEN box motif, which is conserved in chicken and mammalian 
TK1 sequences (Fig 2), located in The C-terminal region of the TK1 protein 
was discovered to have a key role in the mitotic degradation of TK1. Through 
interaction  between  the  KEN  box  motif  and  Cdh1,  an  ubiquitin  ligase  a 
complex is formed leading to TK1 proteolysis. Cdh1 is one of the rates limiting 
factors, which means that the degradation process of TK1 is tightly controlled 25 
in order to balance the dTTP pool and thus, regulate DNA synthesis (Ke & 
Chang, 2004). 
These and other results describing phosphorylation of Ser residue in TK1 
during the cell cycle (Li et al., 2004; Chang et al., 1998; Chang et al., 1994) 
have  led  to  the  following  hypothesis:  in  M  phase  cells,  TK1  is 
hyperphosphorylated, which led to low affinity towards its natural substrate 
dThd.  In S  phase  cells,  TK1 is  hypophosphorylated and  has 10-fold  higher 
affinity  for  dThd  (Chang  et  al.,  1994).  The  residue  that  is  phosphorylated 
during mitosis is Ser 13; however, a mutation of Ser 13 to alanine gave no 
alteration  in the activity  of TK1.  The  wild  type  TK1 may serve as a good 
substrate for Cdc2 kinase but not the mutant enzyme (Chang et al., 1998). 
Substitution  of  Ser  13  with  Asp  to  mimic  its  phosphorylation  gave  a 
decrease in the catalytic activity and affinity toward dThd (Li et al., 2004). 
Furthermore,  it  prevents  the  induction  of  tetramerization  of  TK1  by  ATP. 
During mitosis, TK1 activity is down-regulated by phosphorylation of Ser 13 
giving  a  reduction  of  tetramer  and  dimer  ratio,  resulting  in  low  dTMP 
formation (Li et al., 2004).  
An  overview  illustration  of  this  hypothesis  concerning  the  protein 
expression and catalytic efficiency of TK1 during the cell cycle is presented in 
figure 3. 
 
 
 
Figure 3. A schematic illustration of the fluctuation of thymidine kinase 1 expression during the 
cell cycle adapted from Skovgaard, 2009; Li et al., 2004; Sherley & Kelly, 1988. 26 
In G0/G1 cells, the level of TK1 protein is approximately 30-90 ng/ml and 
it increases up to 4000 ng/ml in S phase cells (Munch-Petersen et al., 1993). 
This suggests that the dimer with low catalytic efficiency is the dominant form 
in G0/G1 regardless of the ATP concentration. However, the tetramer is the 
dominant form in S phase cell, which  gives  high  catalytic capacity of TK1 
(Munch-Petersen et al., 1995a; Munch-Petersen et al., 1995b; Munch-Petersen 
et al., 1993). 
In summary, TK1 protein concentrations, intracellular thymidine and ATP 
concentrations  play  important  roles  in  the  regulation  of  TK1  activity 
throughout the cell cycle. Disturbance in this regulation of TK1 may lead to 
dTTP pool imbalances. 
dTTP can be synthesized by salvage and de novo pathways as described in 
the previous sections, and  the  dTTP pool size is 20-fold  higher in S  phase 
compared to G0 cells (Spyrou & Reichard, 1989). Down regulation of dTTP in 
mitosis, is carried out through APC/C ubiquitin ligase mediates degradation of 
both ribonucleotide reductase R2 subunit and TK1 (Ke & Chang, 2004; Chabes 
et al., 2003). Loss of APC/C mediated proteolysis of TK1 and RNR R2, results 
in  a  significance  elevation  of  the  dTTP  pool  and  hence,  increased  rate  of 
mutations and altered cell growth as well as cell death (Ke et al., 2005). 
3.3  The structure of human TK1 
In 2004, the first three-dimensional structures were solved for the TK1 type 
enzymes i.e. human and Ureaplasma urealyticum TK1 (Welin et al., 2004). 
Shortly thereafter, similar structure of human TK1 was presented by Birringer 
et  al.  in  2005.  The  initial  attempts  to  crystallize  full  length  TK1  were 
unsuccessful,  but  truncated  enzymes  missing  40  residues  in  the  C-terminal 
region were used in these studies (Birringer et al., 2005; Welin et al., 2004).  
The truncated enzyme is a dimer in the absence of ATP and a tetramer in 
the presence of ATP similar to the wild type (Zhu et al., 2006; Munch-Petersen 
et al., 1995a). The enzyme was crystallized in complex with dTTP by Welin 
and coworkers (Welin et al., 2004). The Swiss group did not include dTTP 
during  crystallization,  still  dTTP  was  found  in  the  crystals,  most  likely 
originating from the bacterial metabolism (Birringer et al., 2005).  
The structure of human TK1 is a tetramer; each subunit is composed of two 
domains, α/β domain and a lasso-like domain containing structural zinc. The 
active site is situated between the two domains (Fig 4). 
The α/β domain composed of six parallel β- sheets surrounded by five α- 
helices, which are arranged as follow: on one side, there is a long α- helix and 
flexible loop, and on the other side, there are three short α- helices, which are 27 
similar to the RecA family proteins (Birringer et al., 2005; Welin et al., 2004) 
(Fig. 4 C and D). 
The  tetramer  has  a  central  channel  covered  mainly  by  polar  or  charged 
amino  acids.  The  dimer  is  formed  by  two  different  monomer-monomer 
interactions: one of these is formed from interaction between the long anti-
parallel α- helix from two adjacent subunits, and the second dimer interaction 
is formed from connecting two anti-parallel β- sheets from two subunits via 
water molecules (Welin et al., 2004) (Fig. 4 B).  
 
 
 
 
Figure 2. (A) Monomeric structure of truncated human TK1 with dTTP in the active site. (B) The 
tetramer structure of human TK1. (C) The dimer interaction between subunits A and B. (D) The 
dimer interaction between subunits A and C (Welin et al., 2004).  28 
The  zinc  domain,  from  residues  150  to  191,  forms  part  of  the  substrate 
binding site; it consists of two β-ribbons and a long lasso-like loop, and they 
are kept together by the zinc ion. This zinc ion is bound by four cysteines 153, 
155, 186 and 188 (Fig. 5). Binding of the zinc to these cysteines is of great 
importance for the formation of the correct substrate binding site by stabilizing 
the flexible loop (Birringer et al., 2005; Welin et al., 2004). This region may be 
particularly sensitive to alterations in the redox environment, i.e. in cells and 
the blood. 
The lasso loop from Leu166 to Lys180 forms a long flexible region that 
covers the substrate binding site in TK1 (Fig. 5). The domain is kept in its 
position by hydrogen bonds between the conserved Arg165-Tyr181 and several 
main chain atoms (Birringer et al., 2005; Welin et al., 2004). 
 
 
Figure 5. The lasso domain of thymidine kinase 1. Four cysteines involved in binding the zinc 
containing domain and the lasso loop is stabilized by hydrogen bonds (Welin et al., 2004). 
 
The  substrate  binding  site,  where  the  thymine  base  and  the  feedback 
inhibitor dTTP bind, is buried between the α/β domain and the lasso domain, 
while the phosphate binding site, which is exposed, is located in the P-loop of 
the α/β domain. 
When  an  ATP  analog  and  dThd  are  bound  to  TK1,  the  structures  of 
Thermotoga maritima, Bacillus anthracis, and Bacillus cereus TK;s were very 
similar  to  the  corresponding  TK1-dTTP  complexes.  Furthermore,  the 
quaternary structure of the bacterial TK;s changed upon binding of only ATP, 29 
where the tetramer showed an open state (Segura-Pena et al., 2007a; 2007b). 
However, the human TK1 revealed no electron density for an adenosine group 
when TK1 was crystallized in complex with ATP and thus, no open form of 
human TK1 has been described so far (Kosinska et al., 2007; Segura-Pena et 
al., 2007a; 2007b). 
TK1 has a relatively small substrate binding site, which explains its narrow 
substrate specificity compare to other deoxyribonucleoside kinases (Welin et 
al., 2004). In accordance with the structural studies of different TK;s, described 
above, small substitution at the 5-position of the base, like bromine, fluorine or 
ethyl had no effect on enzyme activity. However, large substitutions at this 
position such as 2- bromovinyl were not accepted as a substrate for human 
TK1(Eriksson et al., 1991a). 
Solving the structures of the human and microbial TK1 is the first step in 
the  design  of  selective  nucleoside  analogs  or  inhibitors,  which  have  low 
affinity to human TK1, but high affinity for bacterial TK;s (Kosinska et al., 
2007; El Omari et al., 2006; Kosinska et al., 2005). These results may lead to 
development of anti-microbial agents based on nucleoside or non-nucleosides, 
which is much needed because of the increased antibiotic resistance observed 
worldwide (Andersson & Hughes, 2012; van Ingen et al., 2012). 
3.4  The role of TK1 in DNA repair 
DNA damaging agents such as radiation, hypoxia and chemotherapy, which 
result in loss of normal cell cycle checkpoints control. Subsequently, genomic 
instability  and  inappropriate  DNA  repair  that  can  lead  to  cell  death  or 
transformation to malignancy (Hartwell & Kastan, 1994). 
One of the mediators that are induced in response to DNA damage and cell 
cycle arrest is p53, a tumor suppressor gene (Smith et al., 2003; Hartwell & 
Kastan, 1994). About 50% of human cancers have alteration or mutation in the 
p53  gene  (Smith  et  al.,  2003).  The  effect  of  activation  of  p53  on  cellular 
growth level and TK1 activity after DNA damage has been defined (Schwartz 
et  al.,  2004;  Rasey  et  al.,  2002).  In  p53  positive  cultured  cells  exposed  to 
different doses of radiation, the percentage of S phase as well as TK1 activity, 
and  3’-  deoxy-  3’-  flourothymidine  (FLT)  uptake  decreased  in  parallel. 
However, in p53 deficient cell the TK1 activity and FLT uptake were high 
even when S phase percentage decreased (Schwartz et al., 2004). Both p53 
positive and negative cell lines show alterations in the cell cycle progression 
and are arrested in the G2  phase after radiation  treatment (Schwartz et al., 
2004).  Thus,  a  functional  p53  is  apparently  needed  for  a  normal 30 
synchronization between TK1 expression and S phase percentage (Swartz et al 
2004). 
Further studies demonstrated that p53 participated in TK1 regulation during 
DNA damage (Chen et al., 2010). It was reported that during DNA recovery, 
TK1 was drastically up-regulated in p53 deficient cells, which are arrested at 
G2  phase,  but  not  in  p53  positive  cells.  Furthermore,  a  translocation  of  a 
fraction TK1 to the nucleus was also observed (Chen et al., 2010). 
Accumulation of TK1 in G2 phase is  most likely due to lack  of  mitotic 
degradation as judged by elevation 4.7-fold in TK1 expression in p21 deficient 
cells (Chen et al., 2010).  
The  dTTP  pool  is  expanded  in  p53  deficient  cells,  in  parallel  with  an 
increased TK1 expression after DNA damage, suggesting that TK1 plays a role 
in  DNA  repair  in  p53  deficient  cells,  providing  a  better  survival  of  cells. 
Furthermore, TK1 depletion during DNA recovery leads to cell death (Chen et 
al., 2010). 
3.5  Thymidine kinase 1 as a cell proliferation biomarker 
The tight coupling between TK1 activity and the cell cycle described in the 
previous  sections  pointed  to  the  usefulness  of  TK1  as  a  reporter  for  cell 
proliferation  and  hence,  for  malignancy.  This  section  will  describe  the 
application  of  TK1  as  a  cell  proliferation  biomarker  in  both  human  and 
veterinary medicine. 
3.5.1  Quantification of serum thymidine kinase 1 
The first method that has been used to quantify TK1 activity in human patients 
with  hematologic  malignancy  was  based  on  phosphorylation  of  radiolabel 
thymidine  to  thymidine  monophosphate  with  ATP  as  a  phosphate  donor 
(Ellims et al., 1981). The procedure was performed using DE-81 paper discs 
and processed as previously described (Ellims & Van der Weyden, 1980). 
In 1980, an optimized method was used to quantify TK1 activity of herpes 
simplex virus Type 1 and 2 using [
125I]-deoxyuridine as a substrate, and the 
procedure was also based on DE-81 paper discs, and the  final product was 
counted using a gamma counter (Gronowitz & Kallander, 1980). Later, this 
assay  was  validated  and  is  commercially  available  (Prolifigen®  TK-REA, 
DiaSorin) to measure TK1 activity in humans with different malignancies such 
as Hodgkin’s and non-Hodgkin’s lymphoma, chronic and acute lymphocytic 
leukemia (Hallek et al., 1999; Hallek et al., 1992; Gronowitz et al., 1983). The 
assay  is  based  on  conversion  the  [
125I]-deoxyuridine  to  [
125I]-deoxyuridine 
monophosphate by TK1 that present in the clinical specimens. The products 31 
are coupled to a granulate matrix, and after several washes, the radioactivity is 
measured  by  a  gamma  counter,  and  the  TK1  activity  is  expressed  as  U/L 
(Gronowitz et al., 1984b). 
Recently, an alternative non-radiometric assay was developed based on the 
thymidine analog AZT. The final product of AZT phosphorylation by TK1, 
AZTMP,  is  determined  by  a  polyclonal  antibody  directed  against  AZTMP 
(Ohrvik et al., 2004). The assay was further developed to a fully automated 
competitive  chemiluminescence  assay  (Liaison  TK  assay,  DiaSorin)  (Von 
Euler et al., 2009). Another ELISA assay, similar to the Liaison technique, is 
used  for  monitoring  patients  with  hematologic  malignancy.  However,  5-
Bromo-deoxyuridine is used as a substrate (DiviTum®) and subsequently, the 
product is incorporated into an oligonucleotide immobilized on the bottom of a 
microtiter  plate;  finally  recombinant  reverse  transcriptase  present  in  the 
DiviTum solution is added. The activity of TK1 is expressed as DiviTum unit 
per  liter  (Du/L).  This  assay  is  claimed  to  give  10-fold  higher  sensitivity 
compared  to  the  TK-REA  assay  (http://biovica.com/?page_id=106  26  Jul. 
2012). 
Recently,  different  polyclonal  and  monoclonal  antibodies  against  human 
TK1 have been produced (Konoplev et al., 2010; O'Neill et al., 2007; Wu et 
al., 2003; Mao et al., 2002; Zhang et al., 2001; He et al., 2000; He et al., 
1996). 
An antibody raised against the 31 amino acid C-terminal part  of  human 
TK1  is  the  most  efficient  and  commonly  used  for  serological  and 
immunohistochemical  detection  of  TK1  in  human  malignancies  such  as 
hematologic  malignancy, breast, lung and bladder cancers (Aufderklamm et 
al.,  2012;  Topolcan  &  Holubec,  2008;  Wu  et  al.,  2003;  Mao  et  al.,  2002; 
Zhang et al., 2001; He et al., 2000; He et al., 1996). An antibody against a 24 
amino acid peptide present at the active site of the TK1 has also been used for 
antibody production and the same applications (Gasparri et al., 2009).  
An advanced technique to measure TK1 activity in vivo is positron emission 
tomography (PET), and it can reflect tumor proliferation rates of tumors in the 
intact animals or persons (Salskov et al., 2007). The most used method is based 
on administration and  monitoring  of the thymidine analog 3’-deoxy-3’-[
18F] 
fluorothymidine  (FLT),  which  is  phosphorylated  by  TK1  into  FLT 
monophosphate, thereby trapped, accumulated and subsequently incorporated 
into the DNA of proliferating cells. The rate limiting step is in most case the 
TK1  catalyzed  reaction,  and  this  imaging  method  can  directly  measure  the 
proliferation  rate  of  tumor  cells  by  following  the  positron  emission  after 
administration of the thymidine analog (Brockenbrough et al., 2011; Salskov et 
al., 2007; Rasey et al., 2002). 32 
3.5.2  The role of serum TK1 in human medicine 
For many decades, elevation of serum thymidine kinase in humans has been 
observed  to  be  associated  with  different  types  of  tumors.  This  section  will 
describe the role of TK1 as a biomarker for the presence of malignancy and its 
diagnostic  and  prognostic  role  in  hematologic  malignancy  and  solid  tumor 
diseases. 
 The levels of serum TK1 in patients with hematologic malignancy 
Level of serum TK1 is elevated in a number of hematologic malignancies such 
as  Hodgkin’s  lymphoma  (HL),  non-Hodgkin’s  lymphoma  (NHL),  acute 
leukemia,  chronic  lymphocytic  leukemia  (CLL),  and  myelodysplastic 
syndrome (MDS). 
In HL, the levels of STK1 in pre-treated patients showed correlation with 
clinical parameters such as histopathology and tumor stage (Eriksson et al., 
1985). High levels of TK1 were found in advanced stage of the disease and 
based on its levels; patients in stage IA and  IIA could be divided into two 
groups with regard to disease-free survival (Eriksson et al., 1985).  
In patients with NHL and multiple myeloma, the level of TK1 correlated 
with clinical stage and grade of the disease (Poley et al., 1997; Hallek et al., 
1992; Hallek et al., 1988; Gronowitz et al., 1983; Ellims et al., 1981). STK1 
levels  provided  prognostic  information  regarding  response  to  therapy  and 
predicted patient’s overall survival (He et al., 2010; Pan et al., 2010; Hallek et 
al.,  1992;  Hagberg  et  al.,  1984a).  Transition  from  indolent  to  progressive 
disease could also be predicted in some cases by an increase in the level of TK 
1, 6 months before symptoms appear (Hallek M et al., 1990). Similar increases 
of  TK1  levels  in  NHL  patients  were  reported  in  a  more  recent  study  (TK 
Liaison) (Ohrvik et al., 2004). 
High STK1 has been reported in patients with acute leukemia (Archimbaud 
et al., 1988; Hagberg et al., 1984c). In a study carried out with children with 
acute  leukemia  (34  lymphocytic,  4  myeloblastic),  TK1  levels  were  highly 
elevated at the time of diagnosis and declined in response to chemotherapy. 
High levels of STK1 were observed in patients with disease relapse one month 
before clinical symptoms appear (Votava et al., 2007). 
In CLL, TK1 provided valuable information in order to distinguish between 
smoldering and non-smoldering disease at an early stage. Moreover, patients 
with non-smoldering CLL can be divided into two groups based on the TK1 
levels  with  different  duration  of  progression-free  survival  (PFS).  STK1 
provided  prognostic  information  independently  of  other  known  prognostic 
factors,  i.e.  patients  with  high  TK1  (>  7.1  U/L)  showed  shorter  PFS  than 
patients with low TK1 level (≤ 7.1 U/L) (Hallek et al., 1999). In 2001, among 33 
188 patients with advanced CLL treated with fludarabine, high level of TK1 
was found in 92% of the patients. That study showed that patients with low 
TK1 level (< 10 U/L) responded to treatment with fludarabine (83%) with a 
median survival rate of 65%, while only 45% of patients with high TK level 
(≥10 U/L)  had a  median survival rate  of 22% (Di Raimondo et al., 2001). 
Thus, this study demonstrated the usefulness of TK1 as a prognostic marker for 
both responses to therapy and duration of survival. Recent studies performed 
with the chemiluminescence assay (TK Liaison) also showed high prognostic 
capacity of STK1 in patients with CLL (Konoplev et al., 2010). Similar results 
were  found  using  the  dot  blot  assay  based  on  anti-TK1  antibodies.  These 
results show that the concentration of TK1 protein in serum can also be used to 
assess the prognosis of patients with CLL (Konoplev et al., 2010; Xu et al., 
2009). 
The  prognostic  relevance  of  STK1  activity  as  a  proliferation  marker  in 
MDS was evaluated in 1995. Patients with high TK1 level (> 38 U/L) had 
shorter survival time than those with low TK1 level (< 38U/L). Furthermore, 
STK1 could predict transformation of MDS to acute myeloid leukemia (AML). 
Multivariate analysis showed that STK1 was the only efficient parameter that 
provides  prognostic  information  for  both  survival  and  response  to  therapy 
(Musto et al., 1995). Similar prognostic  efficiency  for  STK1  measurements 
was  observed  in  adult  T-cell  leukemia  and  AML  patients  (Sadamori  et  al., 
1995). 
Over the past decades, TK 1 has repeatedly been demonstrated to have a 
diagnostic  and  prognostic  role  in  hematologic  malignancies.  By  monitoring 
TK1  levels  in  patients  with  these  types  of  malignancies,  could  provide 
guidance in the selection of a better treatment regimen. 
The levels of serum TK1 in patients with solid tumors 
Several studies investigated the clinical applications of TK1 as a proliferation 
marker in patients with solid tumors such as breast, lung, and bladder, ovarian, 
gastrointestinal and prostatic cancers. 
 Breast cancer has been extensively studied, and the activities of cytosolic TK1 
in tumor samples from about 1700 breast cancer patients were shown to give 
very good prognostic information concerning disease specific survival (DSS) 
and distant-relapse- free interval (DRI) (Broet et al., 2001). In a later study, 
where  the  expression  of  TK1  was  assessed  by  immunohistochemistry  and 
compared with another proliferation marker e.g. PCNA (Mao et al., 2002). The 
level of TK1 correlated to high stages and grades of the disease while PNCA 
did not (Mao et al., 2002). 34 
In 1996, He and coworkers developed polyclonal antibodies against the C-
terminal  region  of  TK1  that  could  be  used  for  both  serum  and 
immunohistochemistry analyses of TK1 in normal and cancer patients (He et 
al., 1996). Subsequently, development of similar antibodies using a 31 mer C-
terminal peptide for immunization of chickens led to the establishment of a dot 
blot assay, which could be used as a marker for monitoring the response of 
therapy in breast cancer patients (He et al., 2000). With the same procedure, 
increased  concentrations  of  TK1  protein  3  months  after  operation  were 
observed in patients developing distant and/or loco-regional relapse during the 
subsequent 5-year period (He et al., 2006). The results were substantiated by 
immunohistochemistry studies, where a significant increase in TK1 expression 
was  found  in  patients  with  high  stage  and  grade  of  tumor  disease.  Higher 
numbers  of  positive  patients  were  obtained  when  a  combination  of  the 
proliferation marker Ki-67 and TK1 was used (He et al., 2004).  
High  levels  of  STK1  protein  were  found  in  preoperative  lung  cancer 
patients with NSCLC, particularly at high stage of the disease, which declined 
significantly  one  month  after  surgery  (Li  et  al.,  2005).  Poor  survival  was 
reported in patients with high TK1 protein levels (Xu et al., 2012). 
The role of TK1 protein determinations as a proliferative marker and for 
monitoring treatment  has been reported in bladder carcinoma (Zhang et al., 
2006), gastrointestinal cancer (Zou et al., 2002), renal cell carcinoma (Luo et 
al., 2009), cervical carcinoma (Fujiwaki et al., 2001), ovarian cancer (Fujiwaki 
et al., 2002), colorectal and prostate cancer (Aufderklamm et al., 2012; O'Neill 
et al., 2001).  
In healthy screening of more than 20 000 apparently healthy persons since 
2005, the level of TK1 was determined by the dot blot assay. Only 0.9% had 
levels of TK1 > 2 pM, which is more than 2 times the SD above the mean TK1 
value of known healthy persons, 80% of the positive persons had proliferation 
related abnormalities in follow  up examinations. These studies  indicate that 
STK1 might be able to predict people at risk of developing a neoplastic disease 
at an early stage (Huang et al., 2011; He et al., 2010; Chen et al., 2008). 
PET  imaging  studies  with  Thd  analogs,  have  been  reported  to  provide 
valuable information regarding the survival, tumor aggressiveness and tumor 
response  to  therapy  in  a  variety  of  human  tumors,  i.e.  lung  cancer,  breast 
cancer, glioma,  head and  neck cancer, esophageal  cancer, but also in some 
hematologic  malignancies  such  as  in  lymphoma  (Wu  et  al.,  2012; 
Brockenbrough et al., 2011; Herrmann et al., 2011a; Herrmann et al., 2011b; 
Richard et al., 2011; Wardak et al., 2011; Buck et al., 2007; Salskov et al., 
2007). However, PET imaging is still not a routine method in most clinical 
situations and particularly not in veterinary medicine. 35 
 
3.5.3  The role of serum TK1 in veterinary medicine  
The  first  study  was  done  in  1997  by  Nakamura  et  al.  and  reported  high 
increases  in  plasma  TK1  activities  in  dogs  with  lymphoma  and  leukemia 
compared with healthy dogs (Nakamura et al., 1997).  
Moreover, the level of  TK1 declined after chemotherapy correlated  with 
reduction  in  tumor  mass.  Two  cases  had  disease  relapse,  and  they  showed 
increased TK1 levels (Nakamura et al., 1997). LDH levels were significantly 
increased  in  dogs  with  lymphoma  and  leukemia,  but  they  were  neither  as 
sensitive nor as specific as TK1 (Nakamura et al., 1997).  
Recent studies on dogs with malignant lymphoma (ML) revealed a similar 
prognostic capability of TK1, where high elevation of TK1 was observed in 55 
dogs  with  malignant  lymphoma  compared  to  healthy  dogs.  Forty-four  dogs 
were followed, and dogs with high TK1 level (> 30 U/L) had shorter overall 
median survival (1 month), whereas dogs with low TK1 level (< 30 U/L) had 
longer survival time (9 months). TK1 was also able to predict disease relapse at 
least 3 weeks before clinical signs appeared (Von Euler et al., 2004). 
Further studies by the same group with 213 dogs mainly with ML (2009; 
Von Euler et al., 2006) demonstrated that the level of TK1 activity in dogs 
with lymphoma out of remission (7-66 U/L) was significantly higher than dogs 
in complete remission (0.5-7.0 U/L). Dogs with leukemia had the highest TK1 
levels (30.7-263 U/L). Although dogs with leukemia out of remission did not 
reach the normal reference range, they had lower TK1 level compared to the 
initial TK1 levels. These studies demonstrate the prognostic capacity of TK1 
for monitoring relapse and response to therapy in dogs with ML. 
In 2011, a study on 73 dogs with lymphoma showed that only 47% of the 
cases had TK1 levels above the normal reference with no correlation to the 
stage of the disease. However, TK1 in dogs that had increased levels, were in 
the normal range during remission (Elliott et al., 2011). 
Some studies have been conducted in dogs with solid tumors with regard to 
serum TK1. Four dogs with different solid tumors were analyzed by Nakamura 
et al. (mammary tumor,  mastocytoma  malignant  histiocytoma, and anal sac 
gland tumor) (Nakamura et al., 1997) and fifty solid tumor cases were tested 
by Von Euler et al. (Von Euler et al., 2009). Surprisingly, the levels of TK1 
were lower than the normal reference range (6.0 U/L) (Nakamura et al., 1997), 
and only 3 cases out of 50 had higher TK1 than healthy dogs (Von Euler et al., 
2009).  The  highest  value  was  observed  in  the  dog  with  advanced  stage 
squamous cell carcinoma (16.2 U/L) and increased levels were found in two 
dogs with splenic hemangiosarcoma (Von Euler & Eriksson, 2011). 36 
Recent studies on dogs with splenic hemangiosarcoma (HAS) demonstrated 
that 80% of dogs with HAS had increased TK1 levels, whereas only some dogs 
with other solid tumors such as osteosarcoma and transitional cell carcinoma 
had high TK1 level (6.7% and 11%, respectively) (Thamm et al., 2011). The 
levels of TK1 were highly elevated in dogs with HAS or other malignancies, 
accompanied by hemoabdomen and a splenic mass, compared to healthy dogs 
or dogs with benign splenic disease. The conclusion from this study was that 
serum TK1 might be useful to distinguish between benign disease and HAS in 
dogs with hemoabdomen and a splenic mass (Thamm et al., 2011). 
3.6  Elevation of Thymidine kinase 1 in non-neoplastic diseases 
STK 1 activities have also been found to be elevated in some viral infections 
such  as  cytomegalovirus  (CMV),  varicella-zoster  virus  (VZV),  Epstein-Bar 
virus  (EBV)  and  herpes  simplex  virus  (HSV)  (Kallander  et  al.,  1989; 
Gronowitz et al., 1986; Larson et al., 1986; Gronowitz et al., 1984a; Kallander 
et al., 1983; Gronowitz et al., 1982; Kallander et al., 1982; Mcguirt et al., 
1982). 
TK1 was also transiently elevated in patients with morbilli and rubella virus 
infections  (Gronowitz  et  al.,  1984b).  Patients  with  acute  hepatitis  also  had 
increased STK1, and the highest levels were observed in patients with hepatitis 
A (Tanaka et al., 1993). 
These studies demonstrated that increased STK activities could be due to a 
virus encoded TK;s (e.g. Herpes virus TK;s) (Gronowitz & Kallander, 1983) 
but  also  to  host  TK1  released  as  a  result  of  damaged  hepatic  cells  or 
inflammatory cells (e.g. in viral Hepatitis) (Tanaka et al., 1993).  
In some malignancy associated with viral infection such as nasopharyngeal 
carcinoma, EBV thymidine kinase protein was the most sensitive marker for 
this type of malignancy (Littler et al., 1991). 
In patients with vitamin B 12 deficiency leading to megaloblastic anemia 
(Hagberg et al., 1984b; Ellims et al., 1980; Hooton & Hoffbrand, 1976), the 
level  of  serum  TK1  increased  often  drastically.  The  rise  of  STK1  in  these 
patients; is most likely due to that the vitamin deficiency disrupting de novo 
thymidylate  synthase  and  leakage  of  TK1  from  destructed  immature 
proliferating blood cells. 
These  conditions  are  relatively  easy  to  identify,  and  thus  false  positive 
results during STK1 analysis in neoplastic disease can be avoided by proper 
medical examinations. 
In veterinary medicine, the activities of STK1 in some dogs with bacterial 
infection  have  been  described  in  the  literature.  i.e.  among  five  dogs  with 37 
tumor-unrelated diseases, one case with canine pyometra and one case with 
tongue  necrosis  showed  increased  STK1  levels,  while  dogs  with  diabetes 
mellitus, seborrheic dermatitis, and upper respiratory infection had low TK1 
levels  (Nakamura  et  al.,  1997).  Another  study  included  14  dogs  with 
unspecified inflammatory diseases, and in this case, the levels of TK1 were all 
within the normal range (Von Euler et al., 2009). 
3.7  Dogs as a model for human diseases 
The  development  of  genomic  techniques  and  release  of  whole  genome 
sequence assemblies have led to a revolution in our understanding of many 
human  and  animal  diseases,  including  cancer.  The  field  of  comparative 
oncology  has also been advanced  greatly because  of  that complete  genome 
sequence  for  veterinary  species  have  been  generated.  Many  investigations 
demonstrate  the  usefulness  of  dogs  as  a  comparative  model  for  complex 
genetic disease, to a large extent as a consequence of mapping of the canine 
disease genes (Wilbe et al., 2010; Breen, 2009).  
Companion animals, primarily dogs and cats with spontaneously occurring 
cancers share many features with human malignancies, e.g. mammary tumors, 
osteosarcoma, lung cancer, soft tissue sarcoma and non-Hodgkin’s lymphoma 
(Macewen,  1990).  Furthermore,  pets  share  to  a  large  extent  the  same 
environmental  carcinogenic  factors as their  owners.  Increased incidences  of 
certain types of tumors in  veterinary  medicine, such as lymphoma  in  dogs, 
provide a large population, shorter lifespan and the relatively large body size 
which are advantages that contribute to the value of dogs as models for human 
oncology (Vail & MacEwen, 2000; Macewen, 1990).  
Although  pets  with  natural  occurring  cancers  are  an  underused  entity 
presently, further investigations can provide excellent  opportunities to study 
many  aspects  basic  oncology,  e.g.  regarding  etiology,  cancer  progression, 
pharmacodynamics, pharmacokinetics, biomarkers and response to treatment. 
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4  Aims of the thesis 
The overall aim of this thesis was to provide a better molecular understanding 
of the serum form(s) of thymidine kinase 1, primarily in dogs with lymphoma. 
This information is essential in deciding how this cell proliferation biomarker 
can be used in cancer treatment and prevention. 
 
 
Specific aims were as following: 
 
￿  To  define  the  difference  in  enzymatic  and  molecular  properties  of 
recombinant dog and  human  TK1, including characterization  of the 
native molecular forms of cytosolic and serum TK1. 
￿  To assess the possibility of use a [
3H]-dThd phosphorylation assay to 
monitor and evaluate the prognosis of dogs with canine lymphoma. 
￿  To evaluate the protein levels of serum TK1 in dogs with hematologic 
malignancies  and  solid  tumors  by  immunoaffinity  techniques. 
Furthermore, to try to assess the correlation between the protein level 
and serum TK activity.  
￿  To determine the effect of reducing agents on the structure and activity 
of TK1. 
￿  To determine whether TK1 activity can be used as a clinical biomarker 
in dogs with bacterial infection diseases such as canine pyometra. 
   40 
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5  Main results and discussion 
Materials and methods that used in the present investigation are described in 
details, in papers I-IV and will not be described here. 
 
5.1.1  Paper I: Quaternary structure of recombinant, cellular, and serum forms 
of thymidine kinase 1 from dogs and humans 
In the first  paper, the  molecular forms  of the cellular and serum thymidine 
kinase 1 protein is studied and compared with the pure recombinant dog as 
well as human enzymes. The enzyme preparations were mainly characterized 
by size exclusion chromatography and immunoaffinity methods.  
Dog and human recombinant TK1 were cloned and expressed in an E.coli 
system  as  described  in  the  methods  section  of  paper  I.  The  substrate 
specificities of both enzymes were determined, as well as their thermal stability 
and pH dependence. The velocity was determined at different concentrations of 
dThd and thymidine analog (AZT) in the presence of a constant concentration 
of  ATP.  When  the  data  was  fitted  to  the  Michaelis-Menten  equation, 
hyperbolic kinetics was observed with Km values for dThd and AZT of 0.9  M 
and 0.7  M, respectively for dog TK1. In case of human TK1, the Km was 0.8 
 M for dThd and 0.65  M for AZT, in agreement with what was previously 
reported (Munch-Petersen et al., 1995b). Both enzymes showed a tendency of 
positive cooperativity with dThd and AZT with Hill coefficients of 1.3 and 1.4, 
respectively.  
The specificity constant (kcat/Km) for AZT with dog TK1 was 3-fold higher 
than that with human TK1. This result may explain why the TK Liaison assay, 
which is based on AZT phosphorylation, gives so reliable results measuring 
TK1  activities  in  canine  leukemia  and  lymphoma  (2009;  Von  Euler  et  al., 
2006).  42 
Dog  recombinant  TK1  was  more  stable,  with  only  16%  of  the  specific 
activity reduced at 50 °C, while with human TK1, the reduction was about 
40% compared to the specific activity at optimal condition (37 °C). 
The subunit composition of recombinant enzyme was determined by size 
exclusion  chromatography  using  Superose  12  column.  Because  of  the  total 
recovery of dog recombinant TK1 in the absence of the reducing agent was 
very low, it was difficult to determine the exact molecular weight of the dog 
recombinant TK1. However, when the enzyme was pre-treated with DTE, both 
the  TK1  activity  and  protein  were  detected,  and  it  was  revealed  that  dog 
recombinant TK1 is in an oligomeric form. 
Oligomer forms were found with human recombinant enzymes, in addition 
to tetramers and dimers, as observed by measuring both TK1 enzyme activities 
and protein levels. This profile differed from what was previously described by 
Munch-Petersen et al. 2009, where they observed that the recombinant enzyme 
occurred mainly as dimers in the absence of ATP and tetramers in the presence 
of  ATP  or  at  a  high  TK1  concentration  in  the  absence  of  ATP  (Munch-
Petersen, 2009). When the enzyme was pre-treated with DTE, a shift toward a 
low molecular weight could be observed, in agreement with the previous study 
(Karlstrom et al., 1990).  
Serum  samples  from  dog  and  human  patients  with  acute  lymphocytic 
leukemia were also characterized by gel filtration. The enzyme activity profile 
of  both  dog  and  human  serum  TK1  was  similar,  eluting  as  oligomers  in 
agreement  with the  only previous study  describing  the  molecular weight  of 
human STK1 (Karlstrom et al., 1990). By western blot analysis, TK1 protein 
bands were found in the same fractions. However, a large fraction of inactive 
tetramer and dimer forms of human TK1 protein was detected.  
Dog sera treated with DTE showed a reduction  in both the activity and 
protein  levels  of  TK1,  but  with  no  shift  in  the  apparent  size  of  the  peaks. 
However,  by  western  blot,  a  minor  peak  with  lower  molecular  weight  was 
observed,  and  inactive  dimer  forms  of  TK1  protein  were  detected.  Human 
STK1 showed minor changes in the MW profile after DTE treatment with a 
reduction in the total activity. However,  no bands  could be  detected in the 
western blot, probably due to that the total recovery of the protein during this 
procedure  was  very  low.  These  results  suggested  that  disulfide  bonds  are 
involved in the large complex formation as suggested previously (Karlstrom et 
al., 1990). Dog TK1 has three cysteines less than human TK1 in the primary 
sequences (Fig 2). This fact may be responsible for the difference in response 
to  reducing  agents.  Further  studies  are  needed  to  determine  which  of  the 
cysteines are involved in the formation of the large complex forms of STK1.  
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5.1.2  Paper II: A sensitive and kinetically defined radiochemical assay for 
canine and human serum thymidine kinase 1 (TK1) to monitor canine 
malignant lymphoma 
 
In this study, we determined if the TK1 activity in serum could serve as a 
proliferation biomarker in dogs and humans with different types of tumours 
using an optimized [
3H]-deoxythymidine phosphorylation assay. The assay was 
compared with the commercially established TK1 enzyme assays, i.e. the TK-
REA and TK Liaison. 
The  kinetic  behavior  and  optimal  conditions  for  determination  of  TK1 
activity  in  serum  from  both  healthy  and  diseased  dogs  and  humans  were 
evaluated. 
Sera from normal dogs and dogs with lymphoma, having different STK1 
activity levels were studied using different substrate concentrations. Data was 
fitted to the Michaelis-Menten equation, and the mean (± SD) Vmax and Km 
values for Thd were 42.1± 34 and 1.2 ±0.4, respectively, in diseased dogs, 
whereas  in  healthy  dogs,  they  were  5.7±  2  and  2.5±  0.8,  respectively.  In 
addition,  the  results  with  human  sera  from  patients  with  hematologic 
malignancy or from healthy subjects showed a substrate inhibition pattern, i.e. 
at Thd concentration ≥ 50  M. 
Inter-assay  and  intra-assay  variations  (CV%)  as  estimated  from  the 
variability of replicated samples were low, i.e. in the range of 2-5%. 
The population in this study was composed of 100 dogs (34 healthy, 29 
with lymphoma, 2 with leukemia, and 35 with solid tumors) and 37 humans 
(18 healthy, 9 with chronic lymphocytic leukemia, 10 with  myelodysplastic 
syndrome).  Some  dogs  with  malignant  lymphoma  were  monitored  during 
chemotherapy courses. 
 
Table 1. Summary of serum thymidine kinase 1 activities in dogs (pmol/min/ml) 
  Mean  Median  Range 
Healthy subjects (n=34)  0.99  0.8  0.5- 2.4 
Hematologic tumor  
patients (n=31) 
24.2  5.5  0.5-243 
Solid tumor patients(n=35)  1.61  0.96  0.4-11.8 
 
The [
3H]-dThd phosphorylation assay had a good accuracy with both dogs 
and humans samples from patients with hematologic malignancy, with the area 
under the curve (the ability of the assay to discriminate between diseased and 44 
non diseased subjects) of 88% and 94%, respectively. The assay also showed 
high  sensitivity  (probability  that  the  test  result  will  be  positive  when  the 
disease is  present, i.e. the true  positive rate) of 94% for dogs and 89% for 
humans. The specificity (probability that the test result will be negative when 
the disease is not present, i.e. the true negative rate) was 67% for dogs and 
74% for humans. 
By  using the Man-Whitney U test,  which  was applicable since the  TK1 
activity  values  were  not  normally  distributed,  the  STK1  activity  was 
significantly higher in sera from dogs with hematologic tumors compared to 
sera from healthy dogs; P ≤ 0.0001.  
Lymphoma dogs with low STK activities were in most cases in complete 
remission, whereas when the disease relapsed, high S-TK activity levels were 
observed. 
It has been shown that TK1 activity values significantly correlated with the 
clinical  stages  of  dog  lymphoma  (Von  Euler  et  al.,  2004).  Although,  the 
sample size was limited in  this study, there was a tendency  of  higher TK1 
activity in stage IV and V cases (Fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 6. Correlation between serum TK1 activities (pmol/min/ml) and different clinical stages of 
malignant lymphoma; stage I and III (n= 18) and Stage IV and V (n= 12). Error bars represent 
SEM. 
The  [
3H]-Thd-assay  correlated  very  well  with  results  obtained  with  TK-
REA and TK Liaison (r = 0.92 and 0.96, P≤ 0.0001, respectively). Hence, the 45 
assay provided fast and a sensitive alternative way to measure TK1 activity, 
avoiding the  drawbacks  of the other  methods, such as complexity and long 
experimental time in the TK-REA (Gronowitz et al., 1983) or interference by 
other serum antibodies and dependence on a particular instrument as in the TK 
Liaison assay (Ohrvik et al., 2004).  
The effectiveness of measurements of STK1 activity in sera from patients 
with solid tumors was low; although four cases in this study showed increased 
TK1  activities  compared  to  the  cut-off  value,  i.e.  synovial  cell  sarcoma, 
histiocytic sarcoma, thymoma, and mammary gland tumor with metastasis in 
the lung. It is not known why these four cases had high STK1 activities while 
the  rest  did  not.  However,  this  result  is  similar  to  what  has  been  reported 
previously  regarding  the  activity  of  STK1  in  dogs  with  solid  tumors  (Von 
Euler et al., 2009; Nakamura et al., 1997). 
Dog STK1 activity was checked at different time points in different assay 
conditions. The enzyme was stable at 4 °C for two weeks and at -20 °C for up 
to seven months and 24 hours at room temperature.  
Human  samples  showed  significantly  increased  STK1  activities  in  the 
hematologic tumor patients group. The highest STK1 values were observed in 
sera from patients with myelodysplastic syndrome. The levels of STK1 most 
likely give an indication of the severity of the disease and the risk to develop 
acute lymphocytic leukemia (Musto et al., 1995).  
  
5.1.3  Paper III: Determination of serum thymidine kinase 1 polypeptide and 
activity levels in dogs with hematologic malignancy and solid tumour 
 
In this study, we wanted to determine the level of TK1 protein in serum from 
dogs with hematologic malignancies, solid tumors and healthy subjects, and to 
assess the correlation between the protein level and TK activity. The effect of 
addition of reducing agents was also studied. 
The study comprised 14 samples from dogs with different malignancies, i.e. 
leukemia (n=2), lymphoma (n=4), solid tumor (n=8) as well as healthy dogs 
(n=7)  The  TK1  26  kDa  subunit  in  sera  from  dogs  with  hematologic 
malignancies,  solid  tumors  and  healthy  subjects  were  quantified  in  parallel 
with STK1 activity measurements. Becuase of the uncertainty of the recovery 
of the immunoaffinity methods for recombinant and STK1, The protein levels 
were  determined  by  measuring  the  bands’  intensities,  and  the  values  were 
expressed as an arbitrary unit (AU). 
Based  on  the  activity,  there  was  a  significant  difference  between 
hematologic malignancy compared to the healthy subjects, but not in the solid 46 
tumor group (Sharif et al., 2012b; Von Euler et al., 2009; Nakamura et al., 
1997).  Similar  results  were  presented  in  this  study,  since  there  was  no 
difference  in  STK1  activity  between  the  solid  tumour  group  and  healthy 
subjects. Moreover, the mean value of the activity in hematologic malignancy 
was approximately 43-fold higher than those found in the solid tumor group. 
However, when the STK1 protein levels were measured, a clear elevation in 
STK1  protein in solid tumor and  hematologic tumor relative to  the  healthy 
controls  were  observed.  Interestingly,  the  mean  value  did  not  differ  in  the 
hematologic malignancy group compared to the solid tumor group (59 and 58 
AU, respectively). 
The relative specific activity of the STK1 protein was determined here for 
the first time, and the result showed about 22-fold higher specific activity in 
case of hematologic malignancies compared to those from patients with solid 
tumors (P= 0.0004). The level of protein in the healthy group was very low, so 
we could not determine the specific activity in this group; however, it must be 
several folds higher than that determined in the solid tumor group.  
Furthermore, there was a significant correlation between STK1 activity and 
TK1 protein concentrations in solid tumor samples (r = 0.85, P < 0.05), in 
agreement  with  some  earlier  studies  that  was  carried  out  in  certain  human 
tumours, e.g. leukemia, breast cancer, and gastric cancer (O'Neill et al., 2007; 
He et al., 2005; Zhang et al., 2001). However, no correlation was observed in 
the  hematologic  malignancy  group,  which  is  most  likely  due  to  the  small 
number of samples in this study. A recent study using immunohistochemistry 
and [
18F]-FLT PET studies demonstrated that there was no correlation between 
TK1  activity  and  TK1  protein  expression  in  25  lung  cancer  patients 
(Brockenbrough et al., 2011). 
The effect of the reducing agent DTE was in accordance with what was 
previously observed (Sharif et al., 2012a), i.e. both the activity and  protein 
levels decreased in response to reducing agents in most samples, except in one 
case with acute myelocytic leukemia, where both the STK1 activity and protein 
levels were elevated.  
The preliminary results are shown here, with a limited number of cases, 
strongly suggest that there is a large fraction of inactive STK1 in soild tumors, 
and STK1 protein seems to be a more sensitive marker for the presence of solid 
tumor compare to STK1 activity.  
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5.1.4  Paper IV: Elevation of serum thymidine kinase 1 activity in a bacterial 
infection: Canine pyometra  
In this study, we aimed to determine whether the level of TK1 is altered in 
non-neoplastic  diseases  such  as  canine  pyometra.  The  relationship  between 
TK1 levels and other biochemical markers as well as hematological parameters 
were also investigated. 
The optimized assay that has been described in paper II was used in this 
study  to  measure  STK1  activity  in  serum  and  plasma  samples.  The  study 
included 94 female dogs (54 dogs with pyometra and 40 healthy dogs). Only 
apparently healthy dogs with hematologic and physical parameters within the 
normal range were included in the control group. 
High correlation between serum and plasma TK1 activity was demonstrated 
(R
2 = 0.96, P < 0.0001); hence, both serum and plasma can be used to measure 
TK1  activity.  STK1  activities  revealed  significant  differences  between  the 
pyometra group and the control group P < 0.05 (Table 2). This result differs, to 
some extent,, from what was previously reported by Von Euler et al. 2009, 
where  healthy  dogs  and  dogs  with  unspecified  inflammatory  diseases  were 
analyzed by the  TK-REA assay (Von Euler et al., 2009). In that study,  no 
significant differences were observed in the TK1 levels. In another study, only 
one case with pyometra was reported, and that case showed an elevation of 
TK1 activity (Nakamura et al., 1997). 
Table 2. Summary of thymidine kinase 1 activities (pmol/min/ml) 
  Mean  Median  Range 
Pyometra group 
(n=54) 
4.0  1.4  0.5-38.6 
Healthy group 
(n=40) 
1.1  1.0  0.66-1.9 
 
Plasma  TK1  activities  were  analyzed  after  ovariohysterectomy  in  some 
cases and the data revealed a significant reduction in TK1 activity in 6 of 10 
diseased dogs one day after surgery. This effect was especially observed in 
individuals that had high TK1 activities (> 1.0 pmol/min/ml), which strongly 
suggest that the increased TK1 levels are caused by the presence of the infected 
uterus. However, the direct mechanism(s) that led to high TK1 activities is still 
unknown. 
Physical examinations,  hematologic, and biochemical parameters, e.g. C-
reactive  protein  (CRP)  and  prostaglandin  F2α  metabolites  (PGM)  were 
analyzed in most of the pyometra cases. These results were used to determine 48 
their correlation with the TK1 levels in the same individuals. No significant 
correlations were found with any of the mentioned parameters. 
 It  has  been  shown  previously  that  the  activity  of  TK1  is  significantly 
correlated with leukocytes in humans (Suehiro et al., 1992). However, in this 
study, no general leukocytosis was observed, since only 54% of the pyometra 
cases showed high leukocyte counts. The fact that a large group of the dogs did 
not  have  increased  leukocytes  is  most  likely  linked  to  the  bone  marrow 
suppression as a result of the severe infection. Furthermore, toxic neutrophils 
and monocyte numbers showed a trend towards a correlation with TK1 activity 
levels (rs= 0.55, P=0.06 and rs=0.3, P= 0.053, respectively). This result may 
indicate a direct link between increased STK1 activity and the severity of the 
infection as reflected by the elevated numbers of band neutrophils and/or the 
monocytosis. If this is due to the leakage of TK1 from destruction of infected 
cells or highly proliferating inflammatory cells remain to be determined. 
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6  Conclusions and future perspectives 
Overall, the results of this thesis contribute to a better understanding of the role 
of serum  thymidine  kinase 1 as a cell  proliferation biomarker in  veterinary 
medicine. More precise conclusions are as following: 
 
 
￿  Serum  thymidine  kinase  1  was  found  as  active  oligomers  with  a 
molecular  weight  of  >  700  kDa  and  inactive  dimer  and  tetramer 
complexes as judged by gel filtration analysis and immunochemical 
methods.  Intra  and  inter  molecular  disulfide  bonds  most  likely 
participate  in  the  formation  of  the  different  complexes  of  serum 
thymidine kinase 1. 
 
￿  An  optimized  [
3H]-Thd  phosphorylation  assay  was  sufficiently 
sensitive  for  measuring  serum  thymidine  kinase  1  in  canine 
hematologic malignancies to be of clinical value. The assay showed a 
significant  correlation  with  the  commercially  available  TK1  assays, 
e.g. TK-REA and TK Liaison. The assay was not sensitive enough for 
routine use in solid tumor diseases. 
 
￿  A 26 kDa polypeptide was observed in sera from dogs with different 
tumors, i.e. both hematologic and solid tumor diseases, using the anti-
dog  TK1  antibody  based  method.  Furthermore,  serum  thymidine 
kinase 1 protein concentrations appear to be effective in distinguishing 
between  healthy  dogs  and  dogs  with  malignancy,  including  solid 
tumors in contrast to serum TK1 activity measurements. 
 
￿  Serum thymidine kinase 1 was significantly elevated in 41% of dogs 
with pyometra caused by bacterial infection. 
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The findings in this thesis increase our knowledge about the role of TK1 in 
both  canine  and  human  medicine,  which  can  be  of  great  help  in  further 
comparative studies. The short life span of pet animals gives an advantage in 
studies of the progression  of  many  diseases, as well as the effectiveness  of 
therapy. Moreover, a health screening test may be designed in dogs where the 
values  of  diagnostic  tests,  e.g.  serum  TK1  determinations,  as  early  disease 
markers can be evaluated much more effectively and at lower costs than in 
humans. 
The  new  results  presented  here  concerning  the  determination  of  STK1 
activity,  and  protein  levels  in  cells  and  serum  in  healthy  and  diseased 
individuals  encourage  the  use  of  both  these  parameters  in  veterinary  and 
human medicine. 
As presented in this investigation, low specific STK1 activity in the solid 
tumor  group  may  or  may  not  mirror  the  proliferation  rate  of  this  type  of 
tumors.  Hence,  the  availability  of  another  parameter,  i.e.  the  STK1  protein 
concentration may overcome the drawback of the other TK1 assays. 
The  difference  in  both  activity  and  protein  level  of  STK1  between 
hematologic  malignancy  and  solid  tumor  might  be  related  to  the  abnormal 
structure  and  function  of  tumor  blood  vessels,  resulting  in  abnormal  tumor 
blood  flow,  increased  blood  pressure  and  hypoxia.  These  conditions  most 
likely could change the structure  of STK1, e.g. to inactive dimers (Munch-
Petersen,  2009;  Carmeliet  &  Jain,  2000).  In  contrast,  in  the  hematologic 
malignancy where TK1 is directly released into the blood, oligomer complexes 
with high TK1 activity are found (Sharif et al., 2012a; Karlstrom et al., 1990). 
The mechanism behind the release of TK1 from solid tumors is not known, but 
is  most  likely  related  to  tumour  cell’s  destruction  (Luo  et  al.,  2009).  The 
abnormal  blood  and  lymphatic  vessels  lead  to  increased  intra-tumor  blood 
pressure, as well as high blood vessel’s permeability, which most likely are 
responsible for the release of inactive TK1 from tumor cells (Jain et al., 2007; 
Carmeliet & Jain, 2000).  
 Fluctuating levels of TK1 in response to chemotherapy provide a measure 
of  the  effectiveness  of  therapy  and  thus,  an  opportunity  to  choose  the  best 
treatment  course  for  the  patients.  Furthermore,  STK1  activity  and  protein 
determinations  are  good  prognostic  tools  giving  information  about  disease 
relapse, most likely improving rescue treatment.  
Elevation of STK1 activity in certain bacterial diseases must be considered 
as an alternative during tumor diagnostic procedures. However, larger studies 
are  needed  in  order  to  confirm  and  explain  the  role  of  TK1  in  bacterial 
infections. 51 
The  results  presented  in  this  thesis  provide  a  starting  point  for  many  new 
studies and some of the most urgent and obvious ones are suggested below. 
 
 
Future perspective and remaining investigations needed: 
 
￿  A mutational analysis of the cysteine residues in dog and human 
TK1;s  to  determine  which  cysteine  residues  that  participated  in 
disulfide cross linking and TK1 oligomer formation. 
￿  Develop  an  ELISA  to  determine  the  dog  TK1  protein  levels  in 
blood,  based  on  the  anti-dog  TK1  antibodies  presented  in  this 
investigation. 
￿  Determine  the  levels  of  serum  TK1  in  a  large  group  of  canine 
pyometra cases, which sample at an early stages of the disease, and 
assess the correlation with other disease markers including those 
for  endotoxemia  to  understand  the  mechanism  responsible  for 
increasing serum TK1 activities. Furthermore, evaluate the level of 
TK1 in other bacterial infection diseases in different animal species 
such as cat, cattle, calf and horse. 
 
 
 
 
   52 
 
   53 
References 
 
 
Andersson, D.I. & Hughes, D. (2012). Evolution of antibiotic resistance at non-
lethal drug concentrations. Drug Resist Updat 15(3), 162-72. 
Archimbaud, E., Vigreux, B., Tigaud, J.D., Maupas, J., Guyotat, D., Viala, J.J. & 
Fiere,  D.  (1988).  Serum  thymidine  kinase  in  acute  nonlymphoblastic 
leukemia. Leukemia 2(4), 245-6. 
Arner,  E.S.  &  Eriksson,  S.  (1995).  Mammalian  deoxyribonucleoside  kinases. 
Pharmacol Ther 67(2), 155-86. 
Aufderklamm, S., Todenhofer, T., Gakis, G., Kruck, S., Hennenlotter, J., Stenzl, A. 
&  Schwentner,  C.  (2012).  Thymidine  kinase  and  cancer  monitoring. 
Cancer Lett 316(1), 6-10. 
Bast, R.C., Jr., Xu, F.J., Yu, Y.H., Barnhill, S., Zhang, Z. & Mills, G.B. (1998). 
CA 125: the past and the future. Int J Biol Markers 13(4), 179-87. 
Bates, S.E. (1991). Clinical applications of serum tumor markers. Ann Intern Med 
115(8), 623-38. 
Birringer, M.S., Claus, M.T., Folkers, G., Kloer, D.P., Schulz, G.E. & Scapozza, L. 
(2005). Structure of a type II thymidine kinase with bound dTTP. FEBS 
Lett 579(6), 1376-82. 
Birringer, M.S., Perozzo, R., Kut, E., Stillhart, C., Surber, W., Scapozza, L. & 
Folkers,  G.  (2006).  High-level  expression  and  purification  of  human 
thymidine kinase 1: quaternary structure, stability, and kinetics. Protein 
Expr Purif 47(2), 506-15. 
Boardman, P.E., Sanz-Ezquerro, J., Overton, I.M., Burt, D.W., Bosch, E., Fong, 
W.T., Tickle, C., Brown, W.R., Wilson, S.A. & Hubbard, S.J. (2002). A 
comprehensive collection of chicken cDNAs. Curr Biol 12(22), 1965-9. 
Bohman, C. & Eriksson, S. (1988). Deoxycytidine kinase from human leukemic 
spleen:  preparation  and  characteristics  of  homogeneous  enzyme. 
Biochemistry 27(12), 4258-65. 
Bradshaw,  H.D.,  Jr.  &  Deininger,  P.L.  (1984).  Human  thymidine  kinase  gene: 
molecular  cloning  and  nucleotide  sequence  of  a  cDNA  expressible  in 
mammalian cells. Mol Cell Biol 4(11), 2316-20. 54 
Bravo, R. & Macdonald-Bravo, H. (1985). Changes in the nuclear distribution of 
cyclin (PCNA) but not its synthesis depend on DNA replication. Embo 
Journal 4(3), 655-61. 
Breen,  M.  (2009).  Update  on  Genomics  in  Veterinary  Oncology.  Topics  in 
Companion Animal Medicine 24(3), 113-121. 
Brockenbrough, J.S., Souquet, T., Morihara, J.K., Stern, J.E., Hawes, S.E., Rasey, 
J.S.,  Leblond,  A.,  Wiens,  L.W.,  Feng,  Q.,  Grierson,  J.  &  Vesselle,  H. 
(2011). Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by 
PET  correlates  with  thymidine  kinase  1  expression:  static  and  kinetic 
analysis  of (18)F-FLT PET studies in lung tumors. J Nucl Med 52(8), 
1181-8. 
Broet, P., Romain, S., Daver, A., Ricolleau, G., Quillien, V., Rallet, A., Asselain, 
B.,  Martin,  P.M.,  Spyratos,  F.  &  Lu,  G.O.F.N.C.  (2001).  Thymidine 
kinase  as  a  proliferative  marker:  Clinical  relevance  in  1,692  primary 
breast cancer patients. Journal of Clinical Oncology 19(11), 2778-2787. 
Brooks, M. (2009). Breast cancer screening and biomarkers. Methods Mol Biol 
472, 307-21. 
Buck, A.K., Kratochwil, C., Glatting, G., Juweid, M., Bommer, M., Tepsic, D., 
Vogg, A.T., Mattfeldt, T., Neumaier, B., Moller, P. & Reske, S.N. (2007). 
Early assessment of therapy response in malignant lymphoma with the 
thymidine  analogue  [18F]FLT.  Eur  J  Nucl  Med  Mol  Imaging  34(11), 
1775-82. 
Carmeliet,  P.  &  Jain,  R.K.  (2000).  Angiogenesis  in  cancer  and  other  diseases. 
Nature 407(6801), 249-57. 
Cass, C.E., Young, J.D., Baldwin, S.A., Cabrita, M.A., Graham, K.A., Griffiths, 
M., Jennings, L.L., Mackey, J.R., Ng, A.M., Ritzel, M.W., Vickers, M.F. 
& Yao, S.Y. (1999). Nucleoside transporters of mammalian cells. Pharm 
Biotechnol 12, 313-52. 
Ceron, J.J., Eckersall, P.D. & Martynez-Subiela, S. (2005). Acute phase proteins in 
dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 
34(2), 85-99. 
Chabes,  A.L.,  Pfleger,  C.M.,  Kirschner,  M.W.  &  Thelander,  L.  (2003).  Mouse 
ribonucleotide reductase R2 protein: a new target for anaphase-promoting 
complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci U S A 100(7), 
3925-9. 
Chang, Z.F., Huang, D.Y. & Chi, L.M. (1998). Serine 13 is the site of mitotic 
phosphorylation  of  human  thymidine  kinase.  Journal  of  Biological 
Chemistry 273(20), 12095-12100. 
Chang, Z.F., Huang, D.Y. & Hsue, N.C. (1994). Differential phosphorylation of 
human  thymidine  kinase  in  proliferating  and  M  phase-arrested  human 
cells. J Biol Chem 269(33), 21249-54. 
Chen,  Y.L.,  Eriksson,  S.  &  Chang,  Z.F.  (2010).  Regulation  and  Functional 
Contribution of Thymidine Kinase 1 in Repair of DNA Damage. Journal 
of Biological Chemistry 285(35), 27327-27335. 55 
Chen, Z., Zhou, H., Li, S., He, E., Hu, J., Zhou, J. & Skog, S. (2008). Serological 
thymidine kinase 1 (STK1) indicates an elevated risk for the development 
of malignant tumours. Anticancer Res 28(6B), 3897-907. 
Chottiner, E.G., Shewach, D.S., Datta, N.S., Ashcraft, E., Gribbin, D., Ginsburg, 
D., Fox, I.H. & Mitchell, B.S. (1991). Cloning and expression of human 
deoxycytidine kinase cDNA. Proc Natl Acad Sci U S A 88(4), 1531-5. 
Coppock, D.L. & Pardee, A.B. (1987). Control of thymidine kinase mRNA during 
the cell cycle. Mol Cell Biol 7(8), 2925-32. 
Di Raimondo, F., Giustolisi, R., Lerner, S., Cacciola, E., O'Brien, S., Kantarjian, 
H. & Keating, M.J. (2001). Retrospective study of the prognostic role of 
serum thymidine kinase level in CLL patients with active disease treated 
with fludarabine. Annals of Oncology 12(5), 621-625. 
Diaz-Padilla, I., Razak, A.R., Minig, L., Bernardini, M.Q. & Maria Del Campo, J. 
(2012).  Prognostic  and  predictive  value  of  CA-125  in  the  primary 
treatment of epithelial ovarian cancer: potentials and pitfalls. Clin Transl 
Oncol 14(1), 15-20. 
Dobrovolsky, V.N., Bucci, T., Heflich, R.H., Desjardins, J. & Richardson, F.C. 
(2003). Mice deficient for cytosolic thymidine kinase gene develop fatal 
kidney disease. Molecular Genetics and Metabolism 78(1), 1-10. 
Duffy, M.J. (2006). Serum tumor markers in breast cancer: Are they of clinical 
value? Clinical Chemistry 52(3), 345-351. 
El Omari, K., Solaroli, N., Karlsson, A., Balzarini, J. & Stammers, D.K. (2006). 
Structure  of  vaccinia  virus  thymidine  kinase  in  complex  with  dTTP: 
insights for drug design. BMC Struct Biol 6, 22. 
Ellims,  P.H.,  Eng  Gan,  T.,  Medley,  G.  &  Van  Der  Weyden,  M.B.  (1981). 
Prognostic  relevance  of  thymidine  kinase  isozymes  in  adult  non-
Hodgkin's lymphoma. Blood 58(5), 926-30. 
Ellims,  P.H.,  Hayman,  R.J.  &  Vanderweyden,  M.B. (1980).  Plasma Thymidine 
Kinase in Megaloblastic-Anemia. British Journal of Haematology 44(1), 
167-168. 
Ellims,  P.H.  &  Van  der  Weyden,  M.B.  (1980).  Human  liver  thymidine  kinase. 
Purification and some properties of the enzyme. J Biol Chem 255(23), 
11290-5. 
Elliott, J.W., Cripps, P. & Blackwood, L. (2011). Thymidine kinase assay in canine 
lymphoma. Vet Comp Oncol. 
Elsevier,  S.M.,  Kucherlapati,  R.S.,  Nichols,  E.A.,  Creagan,  R.P.,  Giles,  R.E., 
Ruddle, F.H., Willecke, K. & McDougall, J.K. (1974). Assignment of the 
gene  for  galactokinase  to  human  chromosome  17  and  its  regional 
localisation to band q21-22. Nature 251(5476), 633-6. 
Eriksson,  B.,  Hagberg,  H.,  Glimelius,  B.,  Sundstrom,  C.,  Gronowitz,  S.  & 
Kallander, C. (1985). Serum thymidine kinase as a prognostic marker in 
Hodgkin's disease. Acta Radiol Oncol 24(2), 167-71. 
Eriksson, S., Kierdaszuk, B., Munch-Petersen, B., Oberg, B. & Johansson, N.G. 
(1991a).  Comparison  of  the  substrate  specificities  of  human  thymidine 56 
kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic 
nucleoside analogs. Biochem Biophys Res Commun 176(2), 586-92. 
Eriksson, S., Munch-Petersen, B., Johansson, K. & Eklund, H. (2002). Structure 
and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 
59(8), 1327-46. 
Eriksson, S., Munch-Petersen, B., Kierdaszuk, B. & Arner, E. (1991b). Expression 
and substrate specificities of human thymidine kinase 1, thymidine kinase 
2 and deoxycytidine kinase. Adv Exp Med Biol 309B, 239-43. 
Ferraris, A.M., Giuntini, P. & Gaetani, G.F. (1979). Serum Lactic-Dehydrogenase 
as a Prognostic Tool for Non-Hodgkin Lymphomas. Blood 54(4), 928-
932. 
Flemington, E., Bradshaw, H.D., Jr., Traina-Dorge, V., Slagel, V. & Deininger, 
P.L.  (1987).  Sequence,  structure  and  promoter  characterization  of  the 
human thymidine kinase gene. Gene 52(2-3), 267-77. 
Fujiwaki, R., Hata, K., Moriyama, M., Iwanari, O., Katabuchi, H., Okamura, H. & 
Miyazaki, K. (2001). Clinical value of thymidine kinase in patients with 
cervical carcinoma. Oncology 61(1), 47-54. 
Fujiwaki, R., Hata, K., Nakayama, K., Moriyama, M., Iwanari, O., Katabuchi, H., 
Okamura,  H.,  Sakai,  E.  &  Miyazaki,  K.  (2002).  Thymidine  kinase  in 
epithelial ovarian cancer: relationship with the other pyrimidine pathway 
enzymes. Int J Cancer 99(3), 328-35. 
Gan, T.E.,  Brumley,  J.L.  &  Van  der  Weyden,  M.B.  (1983).  Human  thymidine 
kinase. Purification and properties of the cytosolic enzyme of placenta. J 
Biol Chem 258(11), 7000-4. 
Gasparri, F., Wang, N.N., Skog, S., Galvani, A. & Eriksson, S. (2009). Thymidine 
kinase  1  expression  defines  an activated  G1  state  of  the  cell  cycle  as 
revealed  with  site-specific  antibodies  and  ArrayScan  (TM)  assays. 
European Journal of Cell Biology 88(12), 779-785. 
Gerdes, J., Schwab, U., Lemke, H. & Stein, H. (1983). Production of a mouse 
monoclonal antibody reactive  with a human nuclear antigen associated 
with cell proliferation. Int J Cancer 31(1), 13-20. 
Gerdes, J., Stein, H., Pileri, S., Rivano, M.T., Gobbi, M., Ralfkiaer, E., Nielsen, 
K.M., Pallesen, G., Bartels, H., Palestro, G. & et al. (1987). Prognostic 
relevance  of  tumour-cell  growth  fraction  in  malignant  non-Hodgkin's 
lymphomas. Lancet 2(8556), 448-9. 
Grogan, T.M., Lippman, S.M., Spier, C.M., Slymen, D.J., Rybski, J.A., Rangel, 
C.S.,  Richter,  L.C.  &  Miller,  T.P.  (1988).  Independent  Prognostic-
Significance  of  a  Nuclear  Proliferation  Antigen  in  Diffuse  Large  Cell 
Lymphomas  as  Determined  by  the  Monoclonal-Antibody  Ki-67.  Blood 
71(4), 1157-1160. 
Gronowitz, J.S., Hagberg, H., Kallander, C.F. & Simonsson, B. (1983). The use of 
serum  deoxythymidine  kinase  as  a  prognostic  marker,  and  in  the 
monitoring of patients with non-Hodgkin's lymphoma. Br J Cancer 47(4), 
487-95. 57 
Gronowitz, J.S. & Kallander, C.F. (1980). Optimized assay for thymidine kinase 
and its application to the detection of antibodies against herpes simplex 
virus type 1- and 2-induced thymidine kinase. Infect Immun 29(2), 425-
34. 
Gronowitz,  J.S.  &  Kallander,  C.F.  (1983).  A  sensitive  assay  for  detection  of 
deoxythymidine kinase and its application to herpesvirus diagnosis. Curr 
Top Microbiol Immunol 104, 235-45. 
Gronowitz, J.S., Kallander, C.F., Jeansson, S. & Wallin, J. (1982). Rapid typing of 
herpes  simplex  virus  based  on  immunological  specificity  of  viral 
thymidine kinase and typing according to sensitivity to iododeoxyuridine. 
J Clin Microbiol 15(3), 366-71. 
Gronowitz, J.S., Kallander, C.F.R., Diderholm, H., Hagberg, H. & Pettersson, U. 
(1984a). Application of an Invitro Assay for Serum Thymidine Kinase - 
Results  on  Viral  Disease  and  Malignancies  in  Humans.  International 
Journal of Cancer 33(1), 5-12. 
Gronowitz,  J.S.,  Kallander,  F.R.,  Diderholm,  H.,  Hagberg,  H.  &  Pettersson,  U. 
(1984b).  Application  of  an  in  vitro  assay  for  serum  thymidine  kinase: 
results on viral disease and malignancies in humans. Int J Cancer 33(1), 
5-12. 
Gronowitz,  J.S.,  Larsson,  A.,  Kallander,  C.F.,  Claesson,  K.,  Sjoberg,  O., 
Lernestedt,  J.O.,  Frodin,  L.  &  Tufveson,  G.  (1986).  Serum  thymidine 
kinase in transplant patients: its relation to cytomegalovirus activity, renal 
transplant rejection and its use for monitoring of antiviral therapy. Ann 
Clin Res 18(2), 71-5. 
Hagberg,  H.,  Glimelius,  B.,  Gronowitz,  S.,  Killander,  A.,  Kallander,  C.  & 
Schroder, T. (1984a). Biochemical markers in non-Hodgkin's lymphoma 
stages  III  and  IV  and  prognosis:  a  multivariate  analysis.  Scand  J 
Haematol 33(1), 59-67. 
Hagberg,  H.,  Gronowitz,  S.,  Killander,  A.  &  Kallander,  C.  (1984b).  Serum 
Thymidine Kinase in Vitamin-B12 Deficiency. Scandinavian Journal of 
Haematology 32(1), 41-45. 
Hagberg,  H.,  Gronowitz,  S.,  Killander,  A.,  Kallander,  C.,  Simonsson,  B., 
Sundstrom, C. & Oberg, G. (1984c). Serum Thymidine Kinase in Acute-
Leukemia. British Journal of Cancer 49(4), 537-540. 
Hallek M, Schick HD, Busch R, Strohmeyer S, Wanders L & B., E. (1990). Serum 
thymidine  kinase  in  low  and  intermediate  grade  non-Hodgkin’s 
lymphoma. Folia Oncol. 13, 87-91. 
Hallek, M., Emmerich, B., Strohmeyer, S., Busch, R., Reichle, A. & Senekowitsch, 
R.  (1988).  Activity  of  serum  thymidine  kinase  in  non-Hodgkin 
lymphoma:  relationship  to  other  prognostic  factors.  Klin  Wochenschr 
66(16), 718-23. 
Hallek, M., Langenmayer, I., Nerl, C., Knauf, W., Dietzfelbinger, H., Adorf, D., 
Ostwald,  M.,  Busch,  R.,  Kuhn-Hallek,  I.,  Thiel,  E.  &  Emmerich,  B. 
(1999).  Elevated  serum  thymidine  kinase  levels  identify  a  subgroup  at 58 
high  risk  of  disease  progression  in  early,  nonsmoldering  chronic 
lymphocytic leukemia. Blood 93(5), 1732-1737. 
Hallek,  M.,  Wanders,  L.,  Strohmeyer,  S.  &  Emmerich,  B.  (1992).  Thymidine 
kinase:  a  tumor  marker  with  prognostic  value  for  non-Hodgkin's 
lymphoma  and  a  broad  range  of  potential  clinical  applications.  Ann 
Hematol 65(1), 1-5. 
Hartwell,  L.H.  &  Kastan,  M.B.  (1994).  Cell  cycle  control  and  cancer.  Science 
266(5192), 1821-8. 
Hatzis, P., Al-Madhoon, A.S., Jullig, M., Petrakis, T.G., Eriksson, S. & Talianidis, 
I. (1998). The intracellular localization of deoxycytidine kinase. J Biol 
Chem 273(46), 30239-43. 
He, E., Xu, X.H., Guan, H., Chen, Y., Chen, Z.H., Pan, Z.L., Tang, L.L., Hu, G.Z., 
Li,  Y.,  Zhang,  M.,  Zhou,  J.,  Eriksson,  S.,  Fornander,  T.  &  Skog,  S. 
(2010).  Thymidine  Kinase  1  is  a  Potential  Marker  for  Prognosis  and 
Monitoring the Response to Treatment of Patients with Breast, Lung, and 
Esophageal  Cancer  and  Non-Hodgkin's  Lymphoma.  Nucleosides 
Nucleotides & Nucleic Acids 29(4-6), 352-358. 
He, Q., Fornander, T., Johansson, H., Johansson, U., Hu, G.Z., Rutqvist, L.E. & 
Skog, S. (2006). Thymidine kinase 1 in serum predicts increased risk of 
distant  or  loco-regional  recurrence  following  surgery  in  patients  with 
early breast cancer. Anticancer Research 26(6C), 4753-4759. 
He, Q., Zou, L., Zhang, P.A., Liu, J.X., Skog, S. & Fornander, T. (2000). The 
clinical  significance  of  thymidine  kinase  1  measurement  in  serum  of 
breast cancer patients using anti-TK1 antibody. International Journal of 
Biological Markers 15(2), 139-146. 
He, Q.M., Ma, Y.R., Wu, J.P., Decker, C., Merza, M., Wang, N.N., Eriksson, S., 
Castro, J. & Skog, S. (2004). Cytosolic thymidine kinase is a specific 
histopathologic  tumour  marker  for  breast  carcinomas.  International 
Journal of Oncology 25(4), 945-953. 
He,  Q.M.,  Skog,  S.,  Wang,  N.N.,  Eriksson,  S.  &  Tribukait,  B.  (1996). 
Characterization of a peptide antibody against a C-terminal part of human 
and  mouse  cytosolic  thymidine  kinase,  which  is  a  marker  for  cell 
proliferation. European Journal of Cell Biology 70(2), 117-124. 
He, Q.M., Zhang, P.G., Zou, L., Li, H.X., Wang, X.Q., Zhou, S., Fornander, T. & 
Skog, S. (2005). Concentration of thymidine kinase 1 in serum (S-TK1) is 
a  more  sensitive  proliferation  marker  in  human  solid  tumors  than  its 
activity. Oncology Reports 14(4), 1013-1019. 
Herrmann,  K.,  Buck,  A.K.,  Schuster,  T.,  Junger,  A.,  Wieder,  H.A.,  Graf,  N., 
Ringshausen, I., Rudelius, M., Wester, H.J., Schwaiger, M., Keller, U. & 
Dechow,  T.  (2011a).  Predictive  value  of  initial  18F-FLT  uptake  in 
patients  with  aggressive  non-Hodgkin  lymphoma  receiving  R-CHOP 
treatment. J Nucl Med 52(5), 690-6. 
Herrmann,  K.,  Buck,  A.K.,  Schuster,  T.,  Rudelius,  M.,  Wester,  H.J.,  Graf,  N., 
Scheuerer,  C.,  Peschel,  C.,  Schwaiger,  M.,  Dechow,  T.  &  Keller,  U. 
(2011b). A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for 59 
initial and early response imaging in mantle cell lymphoma. J Nucl Med 
52(12), 1898-902. 
Hooton, J.W.L. & Hoffbrand, A.V. (1976). Thymidine Kinase in Megaloblastic 
Anemia. British Journal of Haematology 33(4), 527-537. 
Huang, S., Lin, J., Guo, N., Zhang, M., Yun, X., Liu, S., Zhou, J., He, E. & Skog, 
S. (2011). Elevated serum thymidine kinase 1 predicts risk of pre/early 
cancerous progression. Asian Pac J Cancer Prev 12(2), 497-505. 
Ishikawa, K., Sakai, H., Hosoi, M., Yanai, T. & Masegi, T. (2006). Evaluation of 
Cell Proliferation in Canine Tumors by the Bromodeoxyuridine Labeling 
Method, Immunostaining of Ki-67 Antigen and Proliferating Cell Nuclear 
Antigen. Journal of Toxicologic Pathology 19, 123-127. 
Jain, R.K., Tong, R.T. & Munn, L.L. (2007). Effect of vascular normalization by 
antiangiogenic therapy on interstitial hypertension, peritumor edema, and 
lymphatic  metastasis:  insights  from  a  mathematical  model.  Cancer 
Research 67(6), 2729-35. 
Jensen,  H.K.  &  Munch-Petersen,  B.  (1994).  Altered  kinetic  properties  of 
recombinant human cytosolic thymidine kinase (TK1) as compared with 
the native form. Purine and Pyrimidine Metabolism in Man Viii 370, 637-
640. 
Johansson, M., Brismar, S. & Karlsson, A. (1997). Human deoxycytidine kinase is 
located  in  the  cell  nucleus.  Proceedings  of  the  National  Academy  of 
Sciences of the United States of America 94(22), 11941-11945. 
Jullig, M. & Eriksson, S. (2001). Apoptosis induces efflux of the mitochondrial 
matrix enzyme deoxyguanosine kinase. J Biol Chem 276(26), 24000-4. 
Kallander, C.F.R., Gronowitz, J.S. & Oldingstenkvist, E. (1983). Rapid Diagnosis 
of Varicella-Zoster Virus-Infection by Detection of Viral Deoxythymidine 
Kinase  in  Serum  and  Vesicle  Fluid.  Journal  of  Clinical  Microbiology 
17(2), 280-287. 
Kallander, C.F.R., Gronowitz, J.S. & Oldingstenkvist, E. (1989). Varicella Zoster 
Virus Deoxythymidine Kinase Is Present in Serum before the Onset of 
Varicella. Scandinavian Journal of Infectious Diseases 21(3), 255-257. 
Kallander,  C.F.R.,  Gronowitz,  J.S.  &  Torfason,  E.G.  (1982).  Human-Serum 
Antibodies  to  Varicella-Zoster  Virus  Thymidine  Kinase.  Infection  and 
Immunity 36(1), 30-37. 
Karlstrom,  A.R.,  Neumuller,  M.,  Gronowitz,  J.S.  &  Kallander,  C.F.  (1990). 
Molecular  forms  in  human  serum  of  enzymes  synthesizing  DNA 
precursors and DNA. Mol Cell Biochem 92(1), 23-35. 
Kauffman, M.G. & Kelly, T.J. (1991). Cell-Cycle Regulation of Thymidine Kinase 
-  Residues  near  the  Carboxyl  Terminus  Are  Essential  for  the  Specific 
Degradation of the Enzyme at Mitosis. Molecular and Cellular Biology 
11(5), 2538-2546. 
Ke, P.Y. & Chang, Z.F. (2004). Mitotic degradation of human thymidine kinase 1 
is  dependent  on  the  anaphase-promoting  complex/cyclosome-Cdh1-
mediated pathway. Molecular and Cellular Biology 24(2), 514-526. 60 
Ke, P.Y., Kuo, Y.Y., Hu, C.M. & Chang, Z.F. (2005). Control of dTTP pool size 
by  anaphase  promoting  complex/cyclosome  is  essential  for  the 
maintenance  of  genetic  stability.  Genes  &  Development  19(16),  1920-
1933. 
Kiupel, M., Bostock, D. & Bergmann, V. (1998a). The prognostic significance of 
AgNOR  counts  and  PCNA-positive  cell  counts  in  canine  malignant 
lymphomas. J Comp Pathol 119(4), 407-18. 
Kiupel,  M.,  Bostock,  D.E.  &  and  Bergmann,  V.  (1998b).  A  semiquantitative 
method for the evaluation of AgNORs in canine malignant lymphomas. 
European journal of veterinary pathology 4(2). 
Klatzmann, D., Valery, C.A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., 
Diquet, B., Salzmann, J.L. & Philippon, J. (1998). A phase I/II study of 
herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for 
recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. 
Hum Gene Ther 9(17), 2595-604. 
Kong,  W.,  Engel,  K.  &  Wang,  J.  (2004).  Mammalian  nucleoside  transporters. 
Current Drug Metabolism 5(1), 63-84. 
Konoplev, S.N., Fritsche, H.A., O'Brien, S., Wierda, W.G., Keating, M.J., Gornet, 
T.G., St Romain, S., Wang, X., Inamdar, K., Johnson, M.R., Medeiros, 
L.J. & Bueso-Ramos, C.E. (2010). High serum thymidine kinase 1 level 
predicts poorer survival in patients with chronic lymphocytic leukemia. 
Am J Clin Pathol 134(3), 472-7. 
Kornberg, A. & Polliack, A. (1980). Serum Lactic-Dehydrogenase (Ldh) Levels in 
Acute-Leukemia - Marked Elevations in Lymphoblastic-Leukemia. Blood 
56(3), 351-355. 
Kosinska, U., Carnrot, C., Eriksson, S., Wang, L. & Eklund, H. (2005). Structure 
of  the  substrate  complex  of  thymidine  kinase  from  Ureaplasma 
urealyticum and investigations of possible drug targets for the enzyme. 
Febs Journal 272(24), 6365-6372. 
Kosinska, U., Carnrot, C., Sandrini, M.P.B., Clausen, A.R., Wang, L.Y., Piskur, J., 
Eriksson, S. & Eklund, H. (2007). Structural studies of thymidine kinases 
from  Bacillus  anthracis  and  Bacillus  cereus  provide  insights  into 
quaternary structure and conformational changes upon substrate binding. 
Febs Journal 274(3), 727-737. 
Krawiec,  K.,  Kierdaszuk,  B.,  Eriksson,  S.,  Munch-Petersen,  B.  &  Shugar,  D. 
(1995).  Nucleoside  triphosphate  donors  for  nucleoside  kinases:  donor 
properties of  UTP  with human deoxycytidine kinase. Biochem Biophys 
Res Commun 216(1), 42-8. 
Krawiec, K., Kierdaszuk, B., Kalinichenko, E.N., Rubinova, E.B., Mikhailopulo, 
I.A.,  Eriksson,  S.,  Munch-Petersen,  B.  &  Shugar,  D.  (2003).  Striking 
ability  of  adenosine-2  '(3  ')-deoxy-3  '(2  ')-triphosphates  and  related 
analogues to replace ATP as phosphate donor for all four human, and the 
Drosophila  melanogaster,  deoxyribonucleoside  kinases.  Nucleosides 
Nucleotides & Nucleic Acids 22(2), 153-173. 61 
Larson, A., Frodin, L., Tufveson, G., Larsson, E., Kallander, C.F.R. & Gronowitz, 
J.S. (1986). Deoxythymidine Kinase, a Possible Marker for Monitoring 
Activity  of  Cytomegalovirus-Infection  after  Renal-Transplantation. 
Scandinavian Journal of Urology and Nephrology 20(1), 75-76. 
Lechowski, R., Jagielski, D., Hoffmann-Jagielska, M., Zmudzka, M. & Winnicka, 
A. (2002). Alpha-fetoprotein in canine multicentric lymphoma. Veterinary 
Research Communications 26(4), 285-296. 
Lee, L.S. & Cheng, Y.C. (1976). Human deoxythymidine kinase. I. Purification 
and  general  properties  of  the  cytoplasmic  and  mitochondrial  isozymes 
derived  from  blast  cells  of  acute  myelocytic  leukemia.  J  Biol  Chem 
251(9), 2600-4. 
Leoni, L.M., Chao, Q., Cottam, H.B., Genini, D., Rosenbach, M., Carrera, C.J., 
Budihardjo,  I.,  Wang,  X.D.  &  Carson,  D.A.  (1998).  Induction  of  an 
apoptotic program in cell-free extracts by 2-chloro-2 '-deoxyadenosine 5 '-
triphosphate and cytochrome c. Proceedings of the National Academy of 
Sciences of the United States of America 95(16), 9567-9571. 
Li,  C.,  Lu,  C.,  Ke,  P.  &  Chang,  Z.  (2004).  Perturbation  of  ATP-induced 
tetramerization of human cytosolic thymidine kinase by substitution of 
serine-13  with  aspartic  acid  at  the  mitotic  phosphorylation  site. 
Biochemical and Biophysical Research Communications 313(3), 587-593. 
Li, H.X., Zhang, S., Lei, D.S., Wang, X.Q., Skog, S. & He, Q. (2005). Serum 
thymidine kinase 1 is a prognostic and monitoring factor in patients with 
non-small cell lung cancer. Oncology Reports 13(1), 145-149. 
Littler, E.,  Baylis,  S.A.,  Zeng,  Y.,  Conway,  M.J.,  Mackett,  M.  &  Arrand,  J.R. 
(1991).  Diagnosis  of  Nasopharyngeal  Carcinoma  by  Means  of 
Recombinant Epstein-Barr-Virus Proteins. Lancet 337(8743), 685-689. 
Lohr, C.V., Teifke, J.P., Failing, K. & Weiss, E. (1997). Characterization of the 
proliferation  state  in  canine  mammary  tumors  by  the  standardized 
AgNOR method with postfixation and immunohistologic detection of Ki-
67 and PCNA. Vet Pathol 34(3), 212-21. 
Luo, P.C., He, E., Eriksson, S., Zhou, J., Hu, G.Z., Zhang, J. & Skog, S. (2009). 
Thymidine kinase activity in serum of renal cell carcinoma patients is a 
useful prognostic marker. European Journal of Cancer Prevention 18(3), 
220-224. 
Macewen, E.G. (1990). Spontaneous Tumors in Dogs and Cats - Models for the 
Study of Cancer Biology and Treatment. Cancer and Metastasis Reviews 
9(2), 125-136. 
Mao,  Y.,  Wu,  J.,  Wang,  N.,  He,  L.,  Wu,  C.,  He,  Q.  &  Skog,  S.  (2002).  A 
comparative  study:  immunohistochemical  detection  of  cytosolic 
thymidine kinase and proliferating cell nuclear antigen in breast cancer. 
Cancer Invest 20(7-8), 922-31. 
Marconato,  L.,  Crispino,  G.,  Finotello,  R.,  Mazzotti,  S., Salerni,  F.  &  Zini, E. 
(2009).  Serum  lactate  dehydrogenase  activity  in  canine  malignancies. 
Veterinary and Comparative Oncology 7(4), 236-243. 62 
Marconato, L., Crispino, G., Finotello, R., Mazzotti, S. & Zini, E. (2010). Clinical 
relevance of serial determinations of lactate dehydrogenase activity used 
to  predict  recurrence  in  dogs  with  lymphoma.  Javma-Journal  of  the 
American Veterinary Medical Association 236(9), 969-974. 
Mcguirt,  P.V.,  Keller,  P.M.  &  Elion,  G.B.  (1982).  A  Radioimmunoassay  for 
Herpes-Simplex  Virus  (Hsv)  Thymidine  Kinase.  Virology  116(2),  489-
498. 
Merlo, A., Rezende, B.C.G., Franchini, M.L., Simoes, D.M.N. & Lucas, S.R.R. 
(2007). Serum C-reactive protein concentrations in dogs with multicentric 
lymphoma  undergoing  chemotherapy.  Javma-Journal  of  the  American 
Veterinary Medical Association 230(4), 522-526. 
Miller,  O.J.,  Allderdi.Pw,  Miller,  D.A.,  Breg,  W.R.  &  Migeon,  B.R.  (1971). 
Human Thymidine Kinase Gene Locus - Assignment to Chromosome 17 
in a Hybrid of Man and Mouse Cells. Science 173(3993), 244-&. 
Montfort,  W.R.  &  Weichsel,  A.  (1997).  Thymidylate  synthase:  Structure, 
inhibition, and strained conformations during catalysis. Pharmacology & 
Therapeutics 76(1-3), 29-43. 
Munch-Petersen,  B.  (1984).  Differences  in  the  kinetic  properties  of  thymidine 
kinase  isoenzymes  in  unstimulated  and  phytohemagglutinin-stimulated 
human lymphocytes. Mol Cell Biochem 64(2), 173-85. 
Munch-Petersen, B. (2009). Reversible tetramerization of human TK1 to the high 
catalytic  efficient  form  is  induced  by  pyrophosphate,  in  addition  to 
tripolyphosphates, or high enzyme concentration. FEBS J 276(2), 571-80. 
Munch-Petersen,  B.,  Cloos,  L.,  Jensen,  H.K.  &  Tyrsted,  G.  (1995a).  Human 
thymidine  kinase  1.  Regulation  in  normal  and  malignant  cells.  Adv 
Enzyme Regul 35, 69-89. 
Munch-Petersen,  B.,  Cloos,  L.,  Tyrsted,  G.  &  Eriksson,  S.  (1991).  Diverging 
substrate  specificity  of  pure  human  thymidine  kinases  1  and  2 against 
antiviral dideoxynucleosides. J Biol Chem 266(14), 9032-8. 
Munch-Petersen, B., Tyrsted, G. & Cloos, L. (1993). Reversible ATP-dependent 
transition between two forms of human cytosolic thymidine kinase with 
different enzymatic properties. J Biol Chem 268(21), 15621-5. 
Munch-Petersen,  B.,  Tyrsted,  G.,  Cloos,  L.,  Beck,  R.A.  &  Eger,  K.  (1995b). 
Different affinity of the two forms of human cytosolic thymidine kinase 
towards pyrimidine analogs. Biochim Biophys Acta 1250(2), 158-62. 
Murata, H., Shimada, N. & Yoshioka, M. (2004). Current research on acute phase 
proteins in veterinary diagnosis: an overview. Vet J 168(1), 28-40. 
Musto,  P.,  Bodenizza,  C.,  Falcone,  A.,  D'Arena,  G.,  Scalzulli,  P.,  Perla,  G., 
Modoni,  S.,  Parlatore,  L.,  Valvano,  M.R.  &  Carotenuto,  M.  (1995). 
Prognostic  relevance  of  serum  thymidine  kinase  in  primary 
myelodysplastic syndromes: relationship to development of acute myeloid 
leukaemia. Br J Haematol 90(1), 125-30. 
Nakamura, N., Momoi, Y., Watari, T., Yoshino, T., Tsujimoto, H. & Hasegawa, A. 
(1997).  Plasma  thymidine  kinase  activity  in  dogs  with  lymphoma  and 
leukemia. J Vet Med Sci 59(10), 957-60. 63 
Naryzhny,  S.N.  (2008).  Proliferating  cell  nuclear  antigen:  a  proteomics  view. 
Cellular and Molecular Life Sciences 65(23), 3789-3808. 
Nordlund, P. & Reichard, P. (2006). Ribonucleotide reductases. Annual Review of 
Biochemistry 75, 681-706. 
O'Neill,  K.L.,  Buckwalter,  M.R.  &  Murray,  B.K.  (2001).  Thymidine  kinase: 
diagnostic and prognostic potential. Expert Rev Mol Diagn 1(4), 428-33. 
O'Neill, K.L., Zhang, F., Li, H., Fuja, D.G. & Murray, B.K. (2007). Thymidine 
kinase  1  -  A  prognostic  and  diagnostic  indicator  in  ALL  and  AML 
patients. Leukemia 21(3), 560-563. 
Ogilvie, G.K., Walters, L.M., Greeley, S.G., Henkel, S.E. & Salman, M.D. (1993). 
Concentration  of  Alpha(1)-Acid  Glycoprotein  in  Dogs  with  Malignant 
Neoplasia.  Journal  of  the  American  Veterinary  Medical  Association 
203(8), 1144-1146. 
Ohrvik, A., Lindh, M., Einarsson, R., Grassi, J. & Eriksson, S. (2004). Sensitive 
nonradiometric method for determining thymidine kinase 1 activity. Clin 
Chem 50(9), 1597-606. 
Pan,  Z.L.,  Ji,  X.Y.,  Shi,  Y.M.,  Zhou,  J.,  He,  E.  &  Skog,  S.  (2010).  Serum 
thymidine kinase 1 concentration as a prognostic factor of chemotherapy-
treated  non-Hodgkin's  lymphoma  patients.  J  Cancer  Res  Clin  Oncol 
136(8), 1193-9. 
Perkins, G.L., Slater, E.D., Sanders, G.K. & Prichard, J.G. (2003). Serum tumor 
markers. American Family Physician 68(6), 1075-1082. 
Petersen, H.H., Nielsen, J.P. & Heegaard, P.M. (2004). Application of acute phase 
protein measurements in veterinary clinical chemistry. Vet Res 35(2), 163-
87. 
Petty, E.M., Miller, D.E., Grant, A.L., Collins, E.E., Glover, T.W. & Law, D.J. 
(1996). FISH localization of the soluble thymidine kinase gene (TK1) to 
human 17q25, a region of chromosomal loss in sporadic breast tumors. 
Cytogenet Cell Genet 72(4), 319-21. 
Plagemann,  P.G.,  Wohlhueter,  R.M.  &  Woffendin,  C.  (1988).  Nucleoside  and 
nucleobase transport in animal cells. Biochim Biophys Acta 947(3), 405-
43. 
Poley, S., Stieber, P., Nussler, V., Pahl, H. & Fateh-Moghadam, A. (1997). Serum 
thymidine  kinase  in  non-Hodgkin  lymphomas  with  special  regard  to 
multiple myeloma. Anticancer Res 17(4B), 3025-9. 
Preziosi,  R.,  Della  Salda,  L.,  Ricci,  A.,  Simoni,  P.  &  Marcato,  P.S.  (1995). 
Quantification  of  nucleolar  organiser  regions  in  canine  perianal  gland 
tumours. Res Vet Sci 58(3), 277-81. 
Rainov,  N.G.  &  Grp,  G.I.S.  (2000).  A  phase  III  clinical  evaluation  of  herpes 
simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an 
adjuvant  to  surgical  resection  and  radiation  in  adults  with  previously 
untreated glioblastoma multiforme. Human Gene Therapy 11(17), 2389-
2401. 64 
Rasey,  J.S.,  Grierson,  J.R.,  Wiens,  L.W.,  Kolb,  P.D.  &  Schwartz,  J.L.  (2002). 
Validation of FLT uptake as a measure of thymidine kinase-1 activity in 
A549 carcinoma cells. Journal of Nuclear Medicine 43(9), 1210-1217. 
Rau, S., Kohn, B., Richter, C., Fenske, N., Kuechenhoff, H., Hartmann, K., Hartle, 
S., Kaspers, B. & Hirschberger, J. (2007). Plasma interleukin-6 response 
is predictive for severity and mortality in canine systemic inflammatory 
response syndrome and sepsis. Veterinary Clinical Pathology 36(3), 253-
260. 
Reichard,  P.  (1988).  Interactions  between  Deoxyribonucleotide  and  DNA-
Synthesis. Annual Review of Biochemistry 57, 349-374. 
Richard, S.D., Bencherif, B., Edwards, R.P., Elishaev, E., Krivak, T.C., Mountz, 
J.M. & DeLoia, J.A. (2011). Noninvasive assessment of cell proliferation 
in  ovarian  cancer  using  [18F]  3'deoxy-3-fluorothymidine  positron 
emission  tomography/computed  tomography  imaging.  Nucl  Med  Biol 
38(4), 485-91. 
Roels,  S.,  Tilmant,  K.  &  Ducatelle,  R.  (1999).  PCNA  and  Ki67  proliferation 
markers  as  criteria  for  prediction  of  clinical  behaviour  of  melanocytic 
tumours in cats and dogs. Journal of Comparative Pathology 121(1), 13-
24. 
Sadamori, N., Ichiba, M., Mine, M., Hakariya, S., Hayashibara, T., Itoyama, T., 
Nakamura, H., Tomonaga, M. & Hayashi, K. (1995). Clinical significance 
of serum thymidine kinase in adult T-cell leukaemia and acute myeloid 
leukaemia. Br J Haematol 90(1), 100-5. 
Sahin, A.A., Ro, J.Y., el-Naggar, A.K., Wilson, P.L., Teague, K., Blick, M. & 
Ayala,  A.G.  (1991).  Tumor  proliferative  fraction  in  solid  malignant 
neoplasms.  A  comparative  study  of  Ki-67  immunostaining  and  flow 
cytometric determinations. Am J Clin Pathol 96(4), 512-9. 
Sakai,  H.,  Noda,  A.,  Shirai,  N.,  Iidaka,  T.,  Yanai,  T.  &  Masegi,  T.  (2002). 
Proliferative  activity  of  canine  mast  cell  tumours  evaluated  by 
bromodeoxyuridine incorporation and Ki-67 expression. J Comp Pathol 
127(4), 233-8. 
Salskov, A., Tammisetti, V.S., Grierson, J. & Vesselle, H. (2007). FLT: measuring 
tumor cell proliferation in vivo with positron emission tomography and 3'-
deoxy-3'-[18F]fluorothymidine. Semin Nucl Med 37(6), 429-39. 
Sasaroli, D., Coukos, G. & Scholler, N. (2009). Beyond CA125: the coming of age 
of ovarian cancer biomarkers. Are we there yet? Biomark Med 3(3), 275-
288. 
Schneider, R.J., Seibert, K., Passe, S., Little, C., Gee, T., Lee, B.J., 3rd, Mike, V. & 
Young,  C.W.  (1980).  Prognostic  significance  of  serum  lactate 
dehydrogenase in malignant lymphoma. Cancer 46(1), 139-43. 
Schwartz,  J.L.,  Tamura,  Y.,  Jordan,  R.,  Grierson,  J.R.  &  Krohn,  K.A.  (2004). 
Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 
3'-deoxy-3'fluorothymidine uptake. Nucl Med Biol 31(4), 419-23. 65 
Segura-Pena, D., Lichter, J., Trani, M., Konrad, M., Lavie, A. & Lutz, S. (2007a). 
Quaternary  structure  change  as  a  mechanism  for  the  regulation  of 
thymidine kinase 1-like enzymes. Structure 15(12), 1555-1566. 
Segura-Pena,  D.,  Lutz,  S.,  Monnerjahn,  C.,  Konrad,  M.  &  Lavie,  A.  (2007b). 
Binding of ATP to TK1-like enzymes is associated with a conformational 
change in the quaternary structure. Journal of Molecular Biology 369(1), 
129-141. 
Sharif, H., Kiran Kumar, J., Wang, L., He, E. & Eriksson, S. (2012a). Quaternary 
structures of recombinant, cellular, and serum forms of Thymidine Kinase 
1 from dogs and humans. BMC Biochem 13(1), 12. 
Sharif, H., von Euler, H., Westberg, S., He, E., Wang, L. & Eriksson, S. (2012b). A 
sensitive  and  kinetically  defined  radiochemical  assay  for  canine  and 
human  serum  thymidine  kinase  1  (TK1)  to  monitor  canine  malignant 
lymphoma. Vet J. 
Sherley, J.L. & Kelly, T.J. (1988). Regulation of human thymidine kinase during 
the cell cycle. J Biol Chem 263(17), 8350-8. 
Sjoberg, A.H., Wang, L. & Eriksson, S. (1998). Substrate specificity  of human 
recombinant  mitochondrial  deoxyguanosine  kinase  with  cytostatic  and 
antiviral purine and pyrimidine analogs. Mol Pharmacol 53(2), 270-3. 
Skovgaard, T. (2009). Deoxynucleotide Biosynthesis and Regulation: A Study of 
Deoxynucleoside Kinases and Deoxynucleotide Pools. Doctoral thesis. 
Smith, N.D., Rubenstein, J.N., Eggener, S.E. & Kozlowski, J.M. (2003). The p53 
tumor  suppressor  gene  and  nuclear  protein:  basic  science  review  and 
relevance in the management of bladder cancer. J Urol 169(4), 1219-28. 
Song, J.J., Walker, S., Chen, E., Johnson, E.E., 2nd, Spychala, J., Gribbin, T. & 
Mitchell, B.S. (1993). Genomic structure and chromosomal localization of 
the human deoxycytidine kinase gene. Proc Natl Acad Sci U S A 90(2), 
431-4. 
Song, R., Kim, J., Yu, D., Park, C. & Park, J. (2012). Kinetics of IL-6 and TNF-
alpha  changes  in  a  canine  model  of  sepsis  induced  by  endotoxin.  Vet 
Immunol Immunopathol. 
Spyrou, G. & Reichard, P. (1989). Intracellular compartmentation of deoxycytidine 
nucleotide pools in S phase mouse 3T3 fibroblasts. J Biol Chem 264(2), 
960-4. 
Sterman, D.H., Recio, A., Vachani, A., Sun, J., Cheung, L., DeLong, P., Amin, 
K.M., Litzky, L.A., Wilson, J.M., Kaiser, L.R. & Albelda, S.M. (2005). 
Long-term  follow-up  of  patients  with  malignant  pleural  mesothelioma 
receiving  high-dose  adenovirus  herpes  simplex  thymidine 
kinase/ganciclovir suicide gene therapy. Clin Cancer Res 11(20), 7444-
53. 
Stewart, C.J., Ito, M. & Conrad, S.E. (1987). Evidence for transcriptional and post-
transcriptional  control  of  the  cellular  thymidine  kinase  gene.  Mol  Cell 
Biol 7(3), 1156-63. 
Stieber, P., Hatz, R., Holdenrieder, S., Molina, R., Nap, M., Pawel, J., Schalhorn, 
A.,  Schneider,  J.  &  Yamaguchi,  K.  National  Academy  of  Clinical 66 
Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer. 
The National Academy of Clinical Biochemistry. 
Strausberg,  R.L.,  Feingold,  E.A.,  Grouse,  L.H.,  Derge,  J.G.,  Klausner,  R.D., 
Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., 
Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., 
Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., 
Marusina,  K.,  Farmer,  A.A.,  Rubin,  G.M.,  Hong,  L.,  Stapleton,  M., 
Soares, M.B., Bonaldo, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, 
M.J.,  Usdin,  T.B.,  Toshiyuki,  S.,  Carninci,  P.,  Prange,  C.,  Raha,  S.S., 
Loquellano,  N.A.,  Peters,  G.J.,  Abramson,  R.D.,  Mullahy,  S.J.,  Bosak, 
S.A.,  McEwan,  P.J.,  McKernan,  K.J.,  Malek,  J.A.,  Gunaratne,  P.H., 
Richards,  S.,  Worley,  K.C.,  Hale,  S.,  Garcia,  A.M.,  Gay,  L.J.,  Hulyk, 
S.W.,  Villalon,  D.K.,  Muzny,  D.M.,  Sodergren,  E.J.,  Lu, X.H.,  Gibbs, 
R.A.,  Fahey,  J.,  Helton,  E.,  Ketteman,  M.,  Madan,  A.,  Rodrigues,  S., 
Sanchez,  A.,  Whiting,  M.,  Madan,  A.,  Young,  A.C.,  Shevchenko,  Y., 
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, 
M.C.,  Rodriguez,  A.C.,  Grimwood,  J.,  Schmutz,  J.,  Myers,  R.M., 
Butterfield,  Y.S.N.,  Kryzywinski,  M.I.,  Skalska,  U.,  Smailus,  D.E., 
Schnerch, A., Schein, J.E., Jones, S.J.M., Marra, M.A. & Pro, M.G.C.M. 
(2002). Generation and initial analysis of more than 15,000 full-length 
human  and  mouse  cDNA  sequences.  Proceedings  of  the  National 
Academy  of  Sciences  of  the  United  States  of  America  99(26),  16899-
16903. 
Suehiro, M., Fukuchi, M., Kohsaki, M., Takemoto, Y., Kanamaru, A. & Kakishita, 
E. (1992). Serum thymidine kinase, a possible marker for monitoring the 
effect of bone marrow transplant treatment in early recovery phase. Ann 
Nucl Med 6(2), 79-82. 
Tanaka, K., Sishido, T., Morimoto, M., Inoue, S., Takamura, Y. & Masumura, M. 
(1993). Elevated serum thymidine kinase activity in patients with acute 
viral hepatitis. Gastroenterol Jpn 28(1), 51-5. 
Thamm, D.H., Kamstock, D.A., Sharp, C.R., Johnson, S.I., Mazzaferro, E., Herold, 
L.V., Barnes, S.M., Winkler, K. & Selting, K.A. (2011). Elevated serum 
thymidine  kinase  activity  in  canine  splenic  hemangiosarcoma(*).  Vet 
Comp Oncol. 
Thelander,  L.  &  Reichard,  P.  (1979).  Reduction  of  Ribonucleotides.  Annual 
Review of Biochemistry 48, 133-158. 
Topolcan,  O.  &  Holubec,  L.  (2008).  The  role  of  thymidine  kinase  in  cancer 
diseases. Expert Opin. Med. Diagn 2(2), 129-141. 
Tufman, A. & Huber, R.M. (2010). Biological markers in lung cancer: A clinician's 
perspective. Cancer Biomark 6(3-4), 123-35. 
Ural, A.U., Takebe, N., Adhikari, D., Ercikan-Abali, E., Banerjee, D., Barakat, R. 
& Bertino, J.R. (2000). Gene therapy for endometrial carcinoma with the 
herpes simplex thymidine kinase gene. Gynecol Oncol 76(3), 305-10. 
Vail,  D.M.,  Kisseberth,  W.C.,  Obradovich,  J.E.,  Moore,  F.M.,  London,  C.A., 
MacEwen, E.G. & Ritter, M.A. (1996). Assessment of potential doubling 67 
time  (Tpot),  argyrophilic  nucleolar  organizer  regions  (AgNOR),  and 
proliferating  cell  nuclear  antigen  (PCNA)  as  predictors  of  therapy 
response in canine non-Hodgkin's lymphoma. Exp Hematol 24(7), 807-15. 
Vail,  D.M.  &  MacEwen,  E.G.  (2000).  Spontaneously  occurring  tumors  of 
companion  animals as  models  for  human  cancer.  Cancer  Investigation 
18(8), 781-792. 
van Ingen, J., Boeree, M.J., van Soolingen, D. & Mouton, J.W. (2012). Resistance 
mechanisms  and  drug  susceptibility  testing  of  nontuberculous 
mycobacteria. Drug Resist Updat 15(3), 149-61. 
Van  Rompay,  A.R.,  Johansson,  M.  &  Karlsson,  A.  (2000).  Phosphorylation  of 
nucleosides  and  nucleoside  analogs  by  mammalian  nucleoside 
monophosphate kinases. Pharmacology & Therapeutics 87(2-3), 189-198. 
Wang, L., Hellman, U. & Eriksson, S. (1996). Cloning and expression of human 
mitochondrial deoxyguanosine kinase cDNA. FEBS Lett 390(1), 39-43. 
Wang, L., Karlsson, A., Arner, E.S. & Eriksson, S. (1993). Substrate specificity of 
mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-
chlorodeoxyadenosine. J Biol Chem 268(30), 22847-52. 
Wang, L., Saada, A. & Eriksson, S. (2003). Kinetic properties of mutant human 
thymidine  kinase  2  suggest  a  mechanism  for  mitochondrial  DNA 
depletion myopathy. J Biol Chem 278(9), 6963-8. 
Wardak, M., Schiepers, C., Dahlbom, M., Cloughesy, T., Chen, W., Satyamurthy, 
N., Czernin, J., Phelps, M.E. & Huang, S.C. (2011). Discriminant analysis 
of  (1)(8)F-fluorothymidine  kinetic  parameters  to  predict  survival  in 
patients with recurrent high-grade glioma. Clin Cancer Res 17(20), 6553-
62. 
Welin,  M.,  Kosinska,  U.,  Mikkelsen,  N.E.,  Carnrot,  C.,  Zhu,  C.,  Wang,  L., 
Eriksson,  S.,  Munch-Petersen,  B.  &  Eklund,  H.  (2004).  Structures  of 
thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci 
U S A 101(52), 17970-5. 
Wilbe,  M.,  Jokinen,  P.,  Truve,  K.,  Seppala,  E.H.,  Karlsson,  E.K.,  Biagi,  T., 
Hughes, A., Bannasch, D., Andersson, G., Hansson-Hamlin, H., Lohi, H. 
& Lindblad-Toh, K. (2010). Genome-wide association mapping identifies 
multiple loci for a canine SLE-related disease complex. Nature Genetics 
42(3), 250-U39. 
Von Euler, H., Einarsson, R., Olsson, U., Lagerstedt, A.S. & Eriksson, S. (2004). 
Serum  thymidine  kinase  activity  in  dogs  with malignant lymphoma:  a 
potent marker for prognosis and monitoring the disease. J Vet Intern Med 
18(5), 696-702. 
Von  Euler,  H.  &  Eriksson,  S.  (2011).  Comparative  aspects  of  the  proliferation 
marker  thymidine  kinase  1  in human  and  canine  tumour diseases.  Vet 
Comp Oncol 9(1), 1-15. 
Von Euler, H., Ohrvik, A.B. & Eriksson, S.K. (2006). A non-radiometric method 
for measuring serum thymidine kinase activity in malignant lymphoma in 
dogs. Res Vet Sci 80(1), 17-24. 68 
Von  Euler,  H.,  Rivera,  P.,  Aronsson,  A.C.,  Bengtsson,  C.,  Hansson,  L.O.  & 
Eriksson, S.K. (2009). Monitoring therapy in canine malignant lymphoma 
and  leukemia  with  serum  thymidine  kinase  1  activity--evaluation  of  a 
new, fully automated non-radiometric assay. Int J Oncol 34(2), 505-10. 
Votava,  T.,  Topolcan,  O.,  Holubec,  L.,  Jr.,  Cerna,  Z.,  Sasek,  L.,  Finek,  J.  & 
Kormunda,  S.  (2007).  Changes  of  serum  thymidine  kinase  in  children 
with acute leukemia. Anticancer Res 27(4A), 1925-8. 
Wu, C., Yang, R., Zhou, J., Bao, S., Zou, L., Zhang, P., Mao, Y., Wu, J. & He, Q. 
(2003). Production and characterisation of a novel chicken IgY antibody 
raised  against  C-terminal  peptide  from  human  thymidine  kinase  1.  J 
Immunol Methods 277(1-2), 157-69. 
Wu, C.Y., Wang, H.E., Lin, M.H., Chu, L.S. & Liu, R.S. (2012). Radiolabeled 
nucleosides for predicting and monitoring the cancer therapeutic efficacy 
of chemodrugs. Curr Med Chem 19(20), 3315-24. 
Xu, W., Cao, X., Miao, K.R., Qiao, C., Wu, Y.J., Liu, Q., Fan, L. & Li, J.Y. 
(2009). Serum thymidine kinase 1 concentration in Chinese patients with 
chronic lymphocytic leukemia and its correlation with other prognostic 
factors. International Journal of Hematology 90(2), 205-211. 
Xu, Y., Shi, Q.L., Ma, H.H., Zhou, H.B., Lu, Z.F., Yu, B., Zhou, X.J., Eriksson, S., 
He, E.L. & Skog, S. (2012). High thymidine kinase 1 (TK1) expression is 
a predictor of poor survival in patients with pT1 of lung adenocarcinoma. 
Tumor biology 33(2), 475-483. 
Young,  B.,  Gleeson,  M.  &  Cripps,  A.W.  (1991).  C-reactive  protein:  a  critical 
review. Pathology 23(2), 118-24. 
Zanatta,  R.,  Abate,  O.,  D'Angelo,  A.,  Miniscalco,  B.  &  Mannelli,  A.  (2003). 
Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) 
and  LDH  isoenzymes  in  canine  lymphoma.  Veterinary  Research 
Communications 27 Suppl 1, 449-52. 
Zhang, F., Li, H., Pendleton, A.R., Robison, J.G., Monson, K.O., Murray, B.K. & 
O'Neill,  K.L.  (2001).  Thymidine  kinase  1  immunoassay:  a  potential 
marker for breast cancer. Cancer Detect Prev 25(1), 8-15. 
Zhang, J., Jia, Q., Zou, S., Zhang, P., Zhang, X., Skog, S., Luo, P., Zhang, W. & 
He, Q. (2006). Thymidine kinase 1: a proliferation marker for determining 
prognosis  and  monitoring  the  surgical  outcome  of  primary  bladder 
carcinoma patients. Oncol Rep 15(2), 455-61. 
Zhu, C., Harlow, L.S., Berenstein, D., Munch-Petersen, S. & Munch-Petersen, B. 
(2006). Effect of C-terminal of human cytosolic thymidine kinase (TK1) 
on  in  vitro  stability  and  enzymatic  properties.  Nucleosides  Nucleotides 
Nucleic Acids 25(9-11), 1185-8. 
Zimin,  A.V.,  Delcher,  A.L.,  Florea,  L.,  Kelley,  D.R.,  Schatz,  M.C.,  Puiu,  D., 
Hanrahan, F., Pertea, G., Van Tassell, C.P., Sonstegard, T.S., Marcais, G., 
Roberts, M., Subramanian, P., Yorke, J.A. & Salzberg, S.L. (2009). A 
whole-genome assembly of the domestic cow, Bos taurus. Genome Biol 
10(4), R42. 69 
Zou, L., Zhang, P.G., Zou, S., Li, Y. & He, Q. (2002). The half-life of thymidine 
kinase  1  in  serum  measured  by  ECL  dot  blot:  a  potential  marker  for 
monitoring the response to surgery of patients with gastric cancer. Int J 
Biol Markers 17(2), 135-40. 
 
 
   70 
 
   71 
Acknowledgements 
The Prophet Mohammed (peace be upon him) said: ‟ He who does not thank 
people does not thank God” and for this, I would like to offer my regards and 
blessing to those who supported me in any aspect during my study.  
 
First and foremost,  I am  heartily thankful to  my supervisor Staffan, for 
giving me the opportunity to be one of his PhD students. His constant support 
and  guidance  from  the  very  beginning  of  my  PhD  journey  helped  me  to 
develop  an  understanding  of  the  subject.  Thanks  for  interesting  discussions 
about the project, manuscripts and all the help with writing. I would never be 
able  to  finish  this  doctoral  thesis  without  his  immense  patience  and 
encouragements. 
I owe my deepest gratitude to Liya, my co-supervisor, for the endless help 
in the lab and answering all my questions. You never stop to amaze me. 
Ellen, my co-supervisor. Thanks for introducing me to the lab work. The 
experience I have gained from it was worth the hard and tough times I had at 
the beginning. 
I  would  like  to  thank  my  colleagues.  The  SE  group:  Elena,  for  being 
helpful all time, great discussions about TK1 and nice Leo’s picture. Louise, 
thanks for the enjoyable time, sharing various thoughts about life and exciting 
science discussions about enzyme kinetics, Kiran and Ren, for giving me such 
a pleasant time when working together at the lab and for diverting talk about 
everything. Past colleagues: Cecilia and Rahma, thanks for all the help that 
you gave at the beginning of my study. 
My  former  roommates:  Siwei,  Urmi,  and  Diana  and  my  current 
roommates:  Iulia,  Mirjana,  and  Marlene  for  being  such  a  wonderful 
roommates and creating a lovely environment at the office. 
Many  thanks  go  to  the  past  and  present  people  at  the  department  for 
providing a friendly atmosphere to work in and giving me a hand whenever I 
need, Kerstin, Charlotte, Jan, Sara W, Gunnar, Hanna, Andres, Erik, My, 72 
Anton, Anna R, Anna S, Gabriella, Ellin, Ida, Helena, Fabio, Jenny, Sara, 
Ingrid, Mona, Ronnie, Gianni, and Piotr for his indispensable help dealing 
with broken things. 
Henrik, Sara, and Ragnvi, our collaborator at the veterinary clinic, Ruby 
at Akademiska hospital, and Sven from SSTK Inc., thank you all for providing 
us with the samples, encouragement and the great scientific discussions. 
My best friends: Alshaima, thank you for being my companion through all 
these  years  of  great  friendship  and  the  nice  talk  about  life,  religion  and 
sciences. Hanan, I know you for almost all my life even though I have not 
seen you for many years, but the memories of that wonderful time that we had 
together at school, and college have motivated me to go forward. I wish you 
the best with your dissertation. Khadija, Thank you for the nice time. Samira 
and her lovely kids, you inspired me to keep going with my study, thank you 
for everything that you have done for me to feel less home sick. Nagat and 
Fawzia thank you for the lovely time we have spent in Uppsala. Amany, the 
most  ambitious  and  positive  person  I  have  ever  met,  thank  you  for  your 
support, advice and the pleasant company at lunch and “Fikaˮ. Osama, thanks 
for valuable discussion. Juma and Khaled thank you for your encouragement 
and  support.  My  greetings  and  regards  to  my  friends  in  Libya  and  my 
colleagues  at  the  biotechnology  research  center.  I  am  truly  grateful  to  Dr. 
Abdallah Albergli and Dr. Michael Kubista, for all the help and support at 
the beginning. 
I  would like to acknowledge the Libyan Higher Education Board, for their 
financial support for this project.  
Last, but by no means the least my beloved Family for their understanding and 
endless  love,  support,  and  prayers.  I  ♥  you.  Words  fail  me  to  express  my 
appreciation  to  my  soul  mate  Nizar  for  his  support,  encouragement  and 
persistence confidence in me to pursue this degree. I would not have done it 
without his love, patience and understanding. I ♥ you. 
I would like to show my gratitude to the one above all of us, Allah ‟God”, for 
giving me the strength and patience to be able to continue in this study. For 
always being with me, for answering my prayers and making my dreams come 
true. Thank you so much.  
 
 
 
 73 
إ      ا           ا     او و ي  او    أ  ن أ          ا ت     ا             و          اد      
              و    د     أ   ﺻ إ        أ ا           ن  .     آ    و       ﷲ كر   و    ه                
 و          زر أ     ط             ﷲ ل ط  . أ         ♥  
      ,   د    ,        ,       , ة      , ةو    , ةد   و              آ         و ء    ا   ا    ا و     ا ذ   ه       ي
    ط    ذھ ة   ا ه .    
د      ,     ا       و     ار       آ         د        .                      .  
أ   إ         :    ط  ,   د     ,       ,    ح  ,   ن    ,       ,       , أ      ,  و        آ  مد أ     ةد    ا            
    و      ا آ   ا    ا     ذ      ا ةد    ا و    ه       ي أ   د             .  
إ  و          أ  و   ا   أ            آ       ا         .  
إ                 ,       آ     د و          ه                 .  
  
 
 
 
 
 
              Hanan Sharif 
1 August 2012 Uppsala, Sweden 
 
 